UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 13, 2004
Date of Report (Date of earliest event reported)

XLR MEDICAL CORP.
(Exact name of registrant as specified in its charter)

NEVADA   000-59872   88-0488851  
(State or other jurisdiction of  (Commission File  (IRS Employer Identification No.) 
incorporation)  Number)   

Suite 3400 Park Place, 666 Burrard Street    
Vancouver, British Columbia   V6C 3P6  
(Address of principal executive offices)  (Zip Code) 

(604) 676-5247
Registrant's telephone number, including area code

RELAY MINES LIMITED
1040 West Georgia Street, Suite 1160,

Vancouver, British Columbia, Canada

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))


Certain statements contained in this Current Report on Form 8-K constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements, identified by words such as "plan", "anticipate," "believe," "estimate," "should," "expect" and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements reflect the current views of management with respect to future events and are subject to risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from those described in the forward-looking statements. Such risks and uncertainties include those set forth under Section 2 and elsewhere in this Current Report on Form 8-K. We do not intend to update the forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission ("SEC"), particularly our annual reports on Form 10-KSB, our quarterly reports on Form 10-QSB and our current reports on Form 8-K.

SECTION 2 – FINANCIAL INFORMATION.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

Effective on September 13, 2004, pursuant to the Agreement and Plan of Merger (the "First Merger Agreement") dated effective as of August 12, 2004, among Carlo Civelli, Bruno Mosimann, TSI Medical Corp. ("TSI"), Relay Mines Limited (the "Company") and TSI Med Acquisition Corp. ("Relay Sub"), a wholly owned subsidiary of the Company, TSI was merged with and into Relay Sub with Relay Sub continuing as the surviving corporation and as a wholly-owned subsidiary of the Company (the "First Merger").

As discussed below under Item 8.01 of this Current Report, on September 15, 2004, the Company completed a "short form" merger (the "Second Merger") with Relay Sub under the laws of Nevada and changed its name to XLR Medical Corp. Effective on September 15, 2004, the symbol under which the Company trades on the OTC Bulletin Board was changed to "XLRC."

Pursuant to the First Merger Agreement:

(a)      Mr. Civelli and Mr. Mosimann each surrendered 30,000,000 shares of the Company's common stock for cancellation without the payment of any consideration;
 
(b)      9,492,667 shares of TSI common stock were exchanged for 9,492,667 shares of the Company's common stock;
 
(c)      1,450,000 options to acquire shares of TSI common stock at an exercise price of $0.50 per share, expiring on May 31, 2009, were exchanged for 1,450,000 options to acquire shares of the Company's common stock on the same terms and conditions and with the same exercise price as the TSI options; and
 
(d)      54,367 warrants to acquire shares of TSI common stock at a price of $0.75 per share, expiring October 1, 2006, were exchanged for 54,367 warrants to acquire shares of the Company's common stock on the same terms and conditions and at the same exercise price as the TSI warrants.

Also in connection with the First Merger, the Company has assumed the obligations of TSI with respect to a finder's fee to be paid to Imaging Technology Ventures, Inc. ("ITV") and a recent private placement by TSI. As part of the private placement, the Company will issue 500,000 units to subscribers. Each unit will consist of one share of the Company's common stock and one warrant to acquire the

2


Company's common stock at an exercise price of $0.35 per share. The finders fee is payable to ITV for introducing TSI to the business opportunity presented by the EMC Technology described below and will be satisfied by the issuance of 300,000 shares of the Company's common stock.

Corporate Organization and History

The Company was incorporated on February 2, 2001 under the laws of the State of Nevada. Until the Company entered into the First Merger Agreement, the Company's business was focused on the acquisition, exploration and development of mineral properties. Following a recent review of its business, the directors of the Company determined that it was in the best interests of the Company to discontinue its mineral exploration business and to change the focus of the Company's operations to the pursuit of opportunities in the biotechnology field. Following completion of the First Merger and the Second Merger, the Company has acquired an interest in Exelar Medical Corporation ("EMC"), a joint venture company established by TSI and Exelar Corporation ("Exelar") for the purpose of developing a patented technology that utilizes small superconducting magnets to focus and control dosages of therapeutic radiation for the treatment of cancerous tumors (the "EMC Technology").

TSI Medical Corp.

TSI was incorporated under the name Purcell Ventures Inc. on December 21, 2000 under the laws of the State of Nevada. TSI changed its name to TSI Medical Corp. on June 19, 2003. TSI was organized to pursue opportunities in high technology. On March 22, 2004, TSI entered into a Technology Acquisition and Funding Agreement (the "Funding Agreement") with EMC and Exelar, pursuant to which Exelar transferred the EMC Technology to EMC and TSI agreed to provide EMC with funding in the amounts as described below under the heading "Technology Acquisition and Funding Agreement."

The EMC Technology

The EMC Technology utilizes small super-conducting magnets to control therapeutic radiation doses delivered by photon linear accelerators. Accelerators generate therapeutic beams of X-rays (technically called high energy photon beams). Photons are packets of energy that travel though space at the speed of light. An accelerator is to a radiation therapy beam what a flashlight is to a beam of visible light. However, each photon in a flashlight beam carries only about 1/10,000,000th of the energy of a single photon in an accelerator beam. It is this huge scale-up in photon energy that allows an accelerator beam to penetrate into the body to destroy cancer cells within it. The photons from an accelerator are so energetic that when one collides with an electron in a DNA molecule (or any other chemical) in the body, the electron is ejected with great speed and the molecule is disrupted. The recoiling electron travels onward, predominantly in the same direction as the incoming photon. The recoiling electron can penetrate through downstream tissue for some centimeters and on its way destroy many additional molecules. If the molecules are part of the cancer, this contributes to curative effects. If, however, the recoiling electrons travel into healthy tissue belonging to important organs, this can lead to immediately deleterious side-effects and/or significant long-term consequences to the patient.

The EMC Technology is based upon a unique realization that, by applying a locally intense magnetic field to the exterior of the patient's body in the near vicinity of where the photon beam passes through the cancer, one can locally trap significant numbers of the recoiling electrons. The magnetic field causes the recoiling electrons to spiral within the tumor region rather than traveling more or less straight ahead beyond the tumor and into healthy tissue. This patented concept can therefore potentially increase the dosage to a tumor while reducing the exposure of nearby healthy tissue. The magnetic field can also be utilized to simplify alignment of the beam with the tumor and enhance the targeting of moving tumors like those in the lung that shift during respiration.

3


A prototype device incorporating the EMC Technology (the "Device") has been developed by Exelar. The Device employs a single, super-conducting magnet slightly larger than the size of a hockey puck. It operates at near absolute 0° (Kelvin). It is cooled by a commercial low temperature refrigerator (cryo-cooler) and is insulated by an evacuated metal case (thermos bottle). Physically, the Device is the size of a beer keg, with the magnet enclosure the size of a stein. Two pizza box sized units hold the evacuation pump and power source. The unit is attached to a gantry, is easily maneuverable and operates as an add-on device in conjunction with a photon accelerator.

Testing of the Device has been done on "phantom" synthetic tissue. Precision dose data is collected in three dimensions inside the phantom. The results of the testing show these effects:

  1.     
The creation of a "hot spot" of radiation inside the body along the beam with the magnetic field as compared to the beam without the magnetic field.
     
  2.     
A significant reduction in the radiation dose "downstream" beyond the hotspot.
     
  3.     
An indication that the recoiling elections congregate in higher density tissue (such as tumors).

The data from phantom testing indicates 25% to 40% dose enhancement.

The prototype is currently running in a clinical environment on a Varion 2100 C accelerator at Rush-Presbyterian-St. Luke's Medical Centre in Chicago.

Technology Acquisition and Funding Agreement

Pursuant to the Funding Agreement with Exelar and EMC, the Company can acquire a 51% interest in EMC by providing funding to EMC as follows:

    Number of Shares of   Cumulative %
Funding Date   Amount to be Paid   EMC to be Acquired   Ownership of EMC
       
March 25, 2004  $325,000  162,500  6.7%
  (already paid)   
       
June 23, 2004  $575,000  287,500  16.5%
  (already paid)   
       
September 21, 2004  $1,550,000  775,000  35.0%
       
December 20, 2004  $1,000,000  500,000  43.1%
       
March 20, 2005  $1,300,000  650,000  51.0%
       
Total   $4,750,000  2,375,000  51.0%

Under the terms of the Funding Agreement, the Company will receive one share of EMC for each $2.00 of funding provided until a total of $4,750,000 in funding is provided. If the Company defaults on any of its funding obligations, Exelar may, at its option, convert the Company's shares of EMC into non-voting shares, remove all of the Company's nominees to EMC's board of directors and reduce the Company's percentage interest in EMC such that the effective price of the EMC shares will be increased to:

4



(a)      $3.00 per share if the Company defaults on any of the funding requirements to be made on or before September 21, 2004; and
   
(b)      $2.50 per share if the Company defaults on any of the funding requirements to be made after September 21, 2004.

If the Company meets its funding obligations and the board of the directors of EMC determines that additional funding is required to complete the development and commercialization of the EMC Technology, the Company will have the option of increasing its percentage ownership in EMC to 60% by providing an additional $1,500,000 in funding.

Also under the Funding Agreement, Exelar will have the option to convert its shares of EMC into that number of shares of the Company's common stock equal to 49% of the Company's common stock then outstanding at the time of conversion. Exelar's option to convert cannot be exercised until the earliest of the following events has occurred:

(a)      completion of the Company's funding obligations to EMC;
 
(b)      default by the Company of any of its funding obligations to EMC;
 
(c)      March 1, 2005; or
 
(d)      an initial public offering of the Company's stock.

Currently TSI has provided $900,000 in financing under the Funding Agreement and owns approximately 16.5% of EMC, with Exelar owning the remaining 83.5% .

Plan of Operations

The Company's plan of operations for the next twelve months is to meet its funding obligations under the Funding Agreement. As described above, the Company must provide total funding of $3,850,000 to EMC between September 21, 2004 and March 20, 2005 in order to meet its funding obligations. This amount is in excess of the Company's current financial resources and the Company will not be able to proceed with its plan of operations unless it acquires significant additional financing.

The Company plans to pursue equity financing through the sale of shares of its common stock on a private placement basis as it is anticipated that substantial debt financing will not be available to the Company at this stage of its business. Through TSI, the Company currently has in place an arrangement for the private placement of 500,000 units to be issued at $0.35 per unit for total proceeds of $175,000. Each unit will consist of one share of the Company's common stock and one warrant for the acquisition of one share of the Company's common stock at an exercise price of $0.35 per share. The Company does not currently have any other financing arrangements in place and there is no assurance that the Company will be able to acquire sufficient financing in order to allow it to meet its funding obligations to EMC. If the Company is not able to obtain the necessary financing, Exelar may, at its option, reduce the Company's percentage interest in EMC, convert the Company's EMC shares into non-voting shares and/or remove any of the Company's nominees from EMC's board of directors as provided under the Funding Agreement. The Company does not currently have any financing arrangements in place and there is no assurance that the Company will be able to acquire the required financing on or before the dates required under the Funding Agreement.

5


Risk Factors

Need For Financing

The Company will not be able to complete its funding obligations under the Funding Agreement without acquiring substantial additional financing in the near future. If financing is not available or obtainable, the Company's ability to acquire or retain its interest in EMC will be substantially limited and investors may lose a substantial portion or all of their investment. The Company currently does not have sufficient financing arrangements in place to meet its funding obligations to EMC and there is no assurance that the Company will be able to acquire the required financing on acceptable terms or at all.

Limited Operating History, Risks Of A New Business Venture

The Company was incorporated on February 2, 2001 and to date has been involved primarily in organizational and development activities and seeking business opportunities. The Company has had no revenues to date. Potential investors should be aware of the difficulties normally encountered by a new enterprise and the high rate of failure of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties complications and delays encountered in connection with the development of a business in the area in which the Company and EMC intend to operate and in connection with the formation and commencement of operations of a new business in general. These include, but are not limited to, unanticipated problems relating to research and development programs, marketing, approvals by the U.S. Food and Drug Administration (the "FDA"), competition and additional costs and expenses that may exceed current estimates. There is no history upon which to base any assumption as to the likelihood that the Company or EMC will prove successful, and there can be no assurance that the Company or EMC will generate any operating revenues or ever achieve profitable operations.

Our Operations Are Subject To Extensive Government Regulations

EMC's operations will be subject to extensive government regulations in the United States. In order to sell its devices, EMC must satisfy numerous mandatory procedures, regulations, and safety standards established by the federal and state regulatory agencies. There can be no assurance that EMC can successfully comply with all present or future government regulations.

The Health Care Industry Is Subject To Continuing Reform Measures By Governments And Third Party Payors, Which Contribute To The Uncertainty Of Pricing And Reimbursements To Us

The levels of revenue and profitability of medical devices may be affected by government and third party payors for medical services and their continuing efforts to contain or reduce the costs of health care and by initiatives of third party payors with respect to the availability of reimbursements for medical services. In the United States, there have been, and the Company expects that there will continue to be, a number of federal and state proposals to implement similar governmental control. Although the Company cannot predict what legislative reforms may be proposed or adopted or what actions federal, state or private payors for health care services may take in response to any health care reform proposals or legislation, the existence and pendency of such proposals could have a material adverse effect on the Company and EMC.

Whether a medical procedure is subject to reimbursement from third party payors impacts upon the likelihood that a service will be purchased. Third party payors are increasingly challenging the prices charged for medical procedures. There can be no assurance that any procedures using EMC's medical devices will be reimbursable. To the extent that any or all medical procedures using EMC's medical devices are not reimbursable by third party payors, EMC's ability to sell products on a competitive basis will be adversely affected, which could have a material adverse effect on the Company and EMC.

6


Rapid Technological Changes In Our Industry Could Make Our Products Obsolete

The medical devices industry is characterized by rapid technological change and intense competition. New technologies, products and industry standards will develop at a rapid pace which could make EMC's planned product obsolete. The advent of new devices and procedures and advances in new drugs and genetic engineering are especially threatening. The Company and EMC's future success will depend upon EMC's ability to develop and introduce product enhancements to address the needs of its customers. Material delays in introducing product enhancements may cause customers to forego purchases of EMC's product and purchase those of competitors.

EMC Must Receive And Maintain Government Clearances Or Approvals In Order To Market Its Products

EMC's products and future manufacturing activities are subject to extensive, rigorous and changing federal and state regulation in the United States and to similar regulatory requirements in other major international markets, including the European Union and Japan. These regulations and regulatory requirements are broad in scope and govern, among other things:

Furthermore, regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. EMC will be subject to ongoing FDA requirements, including required submissions of safety and other post-market information and reports, registration requirements, quality systems regulations, and recordkeeping requirements. The quality systems regulations include requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation. EMC's prospective distributors, depending on their activities, will also be subject to certain requirements under federal and state laws and registration requirements covering the distribution of products. Regulatory agencies may change existing requirements or adopt new requirements or policies that could affect EMC's regulatory responsibilities or the regulatory responsibilities of a prospective distributor. EMC may be slow to adapt or may not be able to adapt to these changes or new requirements.

Later discovery of previously unknown problems with EMC's products, manufacturing processes, or failure to comply with applicable regulatory requirements may result in enforcement actions by the FDA and other international regulatory authorities, including, but not limited to:


Should any of these enforcement actions occur, the Company and EMC's business, financial condition and results of operations could be materially and adversely affected.

Asserting And Defending Intellectual Property Rights May Impact Results Of Operations

In the medical devices industry, competitors often assert intellectual property infringement claims against one another. The success of EMC's business depends on its ability to successfully defend its intellectual property rights. Future litigation may have a material impact on the Company and EMC's financial condition even if EMC is successful in developing and marketing products. EMC may not be successful in defending or asserting its intellectual property rights.

An adverse outcome in any litigation or interference proceeding could subject EMC to significant liabilities to third parties and require it to cease using the technology that is at issue or to license the technology from third parties. In addition, a finding that any of its intellectual property rights are invalid could allow its competitors to more easily and cost-effectively compete. Thus, an unfavorable outcome in any patent litigation or interference proceeding could have a material adverse effect on the Company and EMC's business, financial condition or results of operations.

The cost to EMC of any patent litigation or interference proceeding could be substantial. Uncertainties resulting from the initiation and continuation of patent litigation or interference proceedings could have a material adverse effect on its ability to compete in the marketplace. Patent litigation and interference proceedings could also absorb significant management time.

EMC May Be Subject To Product Liability Lawsuits

EMC may be subject to product liability claims. The United States Supreme Court has stated that compliance with FDA regulations will not shield a company from common law negligent design claims or manufacturing and labeling claims based on state rules. Such claims may absorb significant management time and could degrade EMC's reputation and the marketability of its products. If product liability claims are made with respect to EMC's products, they may need to recall the implicated product which could have a material adverse effect on the Company and EMC's business, financial condition and results of operations. In addition, although EMC may maintain product liability insurance, it cannot be sure that such insurance will be adequate to cover potential product liability lawsuits. Insurance is expensive and in the future may not be available on acceptable terms, if at all. If a successful product liability claim or series of claims exceeds insurance coverage, it could have a material adverse effect on the Company and EMC's business, financial condition and results of operations.

Competition

The business environment in which EMC intends to operate is highly competitive. EMC expects to experience competition from companies involved in the medical technology industry. Certain of EMC's potential competitors will have greater technical, financial, marketing, sales and other resources than EMC.

Dependence On Key Personnel

The Company's success will largely depend on the performance of its directors and officers and those of EMC. The Company's success will also depend on EMC's ability to attract and retain highly skilled technical, research, management, regulatory compliance, sales and marketing personnel. Competition for such personnel is intense. The loss of the services of such personnel or the inability to attract and retain other key personnel could impair the development of EMC's and consequently the Company's business, operating results and financial condition.

8


Potential Legal, Regulatory, And/Or Compliance Risk

EMC will be required to comply with certain regulations, rules, and/or directives, including FDA approval. If EMC is not able to obtain FDA approval of its device under section 510(k) of the United States Food, Drug and Cosmetic Act as anticipated, it will be required to enter into an expensive and lengthy process to obtain FDA approval for the use of its device. Potential regulatory conditions and/or compliance therewith and the effects of such to EMC, may have a materially adverse affect upon EMC and the Company, their business operations, prospects and/or financial condition.

ITEM 2.04
TRIGERING EVENTS THAT ACCELERATE OR INCREASE A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT

In connection with the First Merger and the Second Merger, the Company has assumed the liabilities of TSI. By a loan agreement dated March 8, 2004, TSI's subsidiary, 689158 B.C. Ltd. borrowed $500,000 from Charles F. White Corp. (the "Lender"). The loan was guaranteed by TSI and was repayable on July 2, 2004 with interest at 12% per annum and a bonus of $80,000. As security for the guarantee, TSI pledged of 826,420 shares in the common stock of TechniScan, Inc. ("TechniScan"). TechniScan is a medical technology company engaged in the business of developing and marketing a proprietary imaging system for detection of breast cancer. The Company has received notice that the loan is in default. The Company is currently in negotiations with the Lender to extend the term of the loan, however there are no assurances that these negotiations will be successful.

SECTION 3 – SECURITITES AND TRADING MARKETS.

ITEM 3.02
UNREGISTERED SALES OF EQUITY SECURITIES

On September 13, 2004, pursuant to the First Merger Agreement, the Company issued the following securities to the former stockholders of TSI:

(a)     
9,492,667 shares of its common stock in exchange for 9,492,667 shares of TSI common stock, being all of the issued and outstanding shares of TSI;
   
(b)     
1,450,000 options (the "Company Options") to purchase shares of the Company's common stock at a price of $0.50 per share in exchange for 1,450,000 options (the "TSI Options") to acquire TSI common stock at the same exercise price; and
   
(c)     
54,367 warrants (the "Company Warrants") to acquire shares of the Company's common stock at a price of $0.75 per share in exchange for 54,367 warrants (the "TSI Warrants") to acquire shares of TSI common stock.

The Company Options were issued with the same terms and conditions as the TSI Options and expire on May 31, 2009. The Company Warrants were issued with the same terms and conditions as the TSI Warrants and expire on October 1, 2006.

The Company issued these shares, options and warrants in connection with the First Merger pursuant to the exemptions to registration contained in Regulation D and Regulation S of the Securities Act of 1933 (the "Securities Act") on the basis that each of the former TSI stockholders has provided representations that they are either "Accredited Investors" as defined in Regulation D or that they are not "U.S. persons" as defined in Regulation S.

9


Shortly after completion of the Second Merger, the Company will issue 500,000 units at a price of $0.35 per unit in connection with a private placement completed by TSI shortly before the First Merger. Each unit will consist of one share of the Company's common stock and a warrant to acquire one share of the Company's common stock at a price of $0.35 per share. These units will be issued to subscribers pursuant to the exemptions to registration contained in Regulation S of the Securities Act on the basis that each of the subscribers has provided representations that they are not "U.S. persons" as defined in Regulation S.

Shortly after completion of the Second Merger, the Company will issue 300,000 shares of its common stock to ITV. These shares are being issued to ITV in satisfaction of a commitment provided by TSI to ITV at the time that TSI entered into the Funding Agreement with EMC and Exelar. At that time, TSI promised to issue 300,000 shares of its common stock to ITV as a finders fee for introducing TSI to Exelar and the business opportunities presented by the EMC Technology. These shares will be issued to ITV pursuant to the exemptions to registration contained in Regulation D of the Securities Act on the basis that ITV has provided representations that it is an "Accredited Investor" as defined in Regulation D.

ITEM 3.03 MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS

On September 12, 2004, the directors of the Company amended and restated the Company's Bylaws in order to adopt a form of Bylaws consistent with those of TSI. The amended and restated Bylaws of the Company contain, among other things, certain changes respecting (i) procedures for the submission of stockholder proposals and nominations of persons for election as directors, (ii) corporate governance and committees of the Company's board of directors and (iii) indemnification of directors and officers. The Company believes that none of these changes constitute a material modification of its Bylaws.

SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT.

ITEM 5.01 CHANGES IN CONTROL OF THE REGISTRANT

(a) Change in Control

Effective on September 13, 2004, as a result of the First Merger as discussed under Item 2.01 of this Current Report, there was a change in control of the Company as follows:

  (i)     
Mr. Civelli and Mr. Mosimann each surrendered 30,000,000 shares in the common stock of the Company, representing, in total, an 81.8 % beneficial ownership in the Company; and
     
  (ii)     
the former stockholders of TSI received a total of 9,492,667 shares of the Company's common stock in exchange for 9,492,667 shares of TSI common stock previously held by them.

As a result of the First Merger, there are now 22,859,875 shares of Relay outstanding, of which the former stockholders of TSI own approximately 41.5% .

As described in Item 5.02 of this Current Report, pursuant to the First Merger Agreement, Mr. Civelli resigned as President, Principal Executive Officer, Treasurer, Principal Financial Officer and as a director of the Company and Mr. Mosimann resigned as Secretary and as a director of the Company and new officers and directors were appointed.

10


(b) Arrangements Which May Result in a Change in Control

Other than the First Merger, there are no arrangements which may result in a change in control of Relay.

ITEM 5.02 DEPARTURES OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

Pursuant to the First Merger Agreement, effective on September 13, 2004, Mr. Civelli resigned as President, Principal Executive Officer, Treasurer, Principal Financial Officer and as a director of the Company and Mr. Mosimann resigned as Secretary and as a director of the Company and new officers and directors were appointed as follows:

  Name   Position(s)  
     
  Logan Anderson  President, Principal Executive Officer, 
    Treasurer, Principal Financial Officer and 
    a Director 
     
  Derek Van Laare  Secretary 
     
  Harold Moll  Director 
     
  Peter Hogendoorn  Director 

Logan Anderson was a director and the president of TSI from January 2002 until May 2003. Mr. Anderson is a graduate of Otago University, New Zealand, with a Bachelor's Degree of Commerce in Accounting and Economics (1977) and is an Associated Chartered Accountant (New Zealand). Mr. Anderson is the Chief Executive Officer and a director of Worldbid Corporation (a business to business Internet company). Mr. Anderson was appointed as a director of Worldbid Corporation on August 10, 1998 and was appointed as the Chief Executive Officer of Worldbid Corporation on July 31, 2001.

Derek Van Laare served as a director and as the president, secretary and treasurer of TSI from May 2003 until the date of the First Merger. Mr. Van Laare had previously served as the Vice-President of TSI from June 2002 until May 2003. Mr. Van Laare is a former securities broker and has over 25 years of experience in financing public companies. Mr. Van Laare has served as a director and officer of several public companies, including PLC Systems, Inc., 3-D Systems Inc. and ID Biomedical Corporation.

Harold Moll served as the chairman and as a director of TSI from January 2002 until the date of the First Merger. Mr. Moll has been a self-employed financier and business executive since 1960. He is a former director and officer of a number of public companies, including PLC Systems, Inc. and 3-D Systems Inc. Prior to January 2002, Mr. Moll had been retired.

Peter A. Hogendoorn has been the president and owner of 499375 BC Limited since 1993, a consulting firm for numerous start-ups and junior public companies, including: International Wayside Goldmines (IWA:TSX), Integral Technologies (ITKG:OTCBB), Cryopak, LML Payment Systems (LMLP:NASDAQ), NS8 Corporation (NSEO:OTCBB). Mr. Hogendoorn acted as the Chief Executive Officer and a director of NS8 Corporation, a public company, from January 2003 to July 2004. NS8 Corporation developed two primary patent pending technologies that changed the way digital content is delivered and secured over IP based systems. Mr. Hogendoorn was responsible for expanding NS8 Corporation from 9 employees to 45, leading it from R&D to commercial deployment, developing its business plan from a

11


subscriber based direct to consumer model to a middleware and licensing model and raising all operating capital (approx $9 million). Mr. Hogendoorn continues to consult for NS8 Corporation in its capital markets objectives and financing activities. From 1997 to 2002, Mr. Hogendoorn was employed by LML Payment Systems Inc. to initiate and maintain a comprehensive investor relations program and assist in financing initiatives. LML developed and market patented payment processing systems in the U.S. for converting checking account based transactions into electronic check conversions, eliminating the actual paper in the process.

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

As discussed above under Item 3.03 of this Current Report on Form 8-K, on September 12, 2004, the Company amended and restated its Bylaws. The amended and restated Bylaws of the Company are attached as Exhibit 3.1 to this Current Report.

SECTION 8 – OTHER EVENTS.

ITEM 8.01 OTHER EVENTS

On September 15, 2004, the Company completed a "short form" merger with Relay Sub (the "Second Merger") under the laws of Nevada and changed its name to XLR Medical Corp. Under the plan of merger, each outstanding share of Relay Sub common stock was exchanged for one share of the Company's common stock. There has been no change to the Company's Articles of Incorporation other than the name change to XLR Medical Corp. The Agreement and Plan of Merger between the Company and Relay Sub is filed as an exhibit to this Current Report on Form 8-K. Effective on September 15, 2004, the symbol under which the Company trades on the OTC Bulletin Board was changed to "XLRC."

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(a)      
Financial Statements of Business Acquired
 
 
The historical financial statements of TSI are not included in this Current Report and will be filed by an amendment to this Current Report no later than November 29, 2004.
 
(b)      
Pro Forma Financial Information
 
 
Pro forma consolidated financial statements of the Company and TSI are not included in this Current Report and will be filed by an amendment to this Current Report no later than November 29, 2004.

12



(c) Exhibits

Exhibit    
Number   Description of Exhibit
     
2.1  
     
3.1  
     
3.2  
Articles of Incorporation for Relay Mines Limited. (1)
     
3.3  
     
10.1  
     
10.2  
Agreement and Plan of Merger between Carlo Civelli, Bruno Mosimann, TSI Medical Corp., Relay Mines Limited and TSI Med Acquisition Corp., dated effective as of August 12, 2004. (2)
     
99.1   Press Release.

  (1)      Previously filed as an exhibit to the Company's Registration Statement on Form SB-2 filed with the SEC on May 1, 2001.
     
  (2)      Previously filed as an exhibit to the Company's Current Report on Form 8-K filed with the SEC on August 20, 2004.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  XLR MEDICAL CORP.  
     
Date:  September 17, 2004     
  By:  /s/ Logan B. Anderson  
    Logan B. Anderson 
    President, Principal Executive Officer, 
    Treasurer and Principal Financial Officer 

13



AGREEMENT AND PLAN OF MERGER

This Agreement And Plan Of Merger dated as of the 13th day of September, 2004.

BETWEEN:

RELAY MINES LIMITED (a Nevada Corporation), having its office a Nevada corporation with its principal office at 1040 West Georgia Street, Suite 1160, Vancouver, British Columbia, Canada V6E 4H1

("Relay")

OF THE FIRST PART

AND:

TSI MED ACQUISITION CORP. (a Nevada Corporation), having its registered office at 3273 East Warm Springs Road, Las Vegas, Nevada 89120

("Relay Sub")

OF THE SECOND PART

WHEREAS:

A.                  This Agreement and Plan of Merger (this "Agreement") is made and entered into as of September 13, 2004 between Relay and Relay Sub. Relay and Relay Sub are from time to time herein referred to as the "Constituent Corporations";

B.                  Relay Sub is the wholly-owned subsidiary of Relay and is a corporation duly organized and existing under the laws of the State of Nevada;

C.                  Each of the Boards of Directors of the Constituent Corporations deem it advisable and in the best interests of Constituent Corporations and their respective shareholders that Relay Sub be merged with and into its parent, Relay;

D.                  By directors' resolution dated September 13, 2004, the Board of Directors of Relay Sub has approved the Plan of Merger embodied in this Agreement.

E.                  By directors' resolution dated September 13, 2004, the Board of Directors of Relay has approved the Plan of Merger embodied in this Agreement.

NOW THEREFORE , in consideration of the mutual agreements and covenants set forth herein, the Constituent Corporations do hereby agree to merge on the terms and conditions herein provided, as follows:


- 2 -

1.                  THE MERGER

1.1                The Merger

                      Upon the terms and subject to the conditions hereof, on the Effective Date (as hereinafter defined), Relay Sub shall be merged with and into Relay in accordance with the applicable laws of the State of Nevada (the "Merger"). The separate existence of Relay Sub shall cease, and Relay shall be the surviving corporation (the "Surviving Corporation") and shall be governed by the laws of the State of Nevada.

1.2                 Effective Date

                      The merger shall become effective on the date and at the time of filing of Articles of Merger, in substantially the form annexed hereto as Appendix A, with the Secretary of State of the State of Nevada, (the "Effective Date"), all after satisfaction of the requirements of the applicable laws of Nevada prerequisite to such filings.

1.3                 Articles of Incorporation

                      On the Effective Date, the Articles of Incorporation of Relay, as in effect immediately prior to the Effective Date, shall continue in full force and effect as the Articles of Incorporation of the Surviving Corporation, except that Article 1 of the Articles of Incorporation of Relay, as the Surviving Corporation, shall be amended to state that the name of the corporation is "XLR Medical Corp."

1.4                 Bylaws

                      On the Effective Date, the Bylaws of Relay, as in effect immediately prior to the Effective Date, shall continue in full force and effect as the bylaws of the Surviving Corporation.

1.5                 Directors and Officers

                      The directors and officers of Relay immediately prior to the Effective Date shall be the directors and officers of the Surviving Corporation, until their successors shall have been duly elected and qualified or until otherwise provided by law, the Articles of Incorporation of the Surviving Corporation or the Bylaws of the Surviving Corporation.

1.6                 Conditions Precedent to Closing by Relay

                      The obligations of Relay to consummate the Merger is subject to the completion of the merger contemplated by the agreement and plan of merger dated August 12, 2004 among Relay, Relay Sub, TSI Medical Corp., a Nevada corporation, Carlo Civelli and Bruno Mosimann. The Closing of the Merger contemplated by this Agreement will be deemed to mean a waiver of all conditions to Closing. This condition of closing is for the benefit of Relay and may be waived by Relay in its discretion.

2.                  CONVERSION OF SHARES

2.1                 Relay Common Stock

                      Upon the Effective Date, by virtue of the Merger and without any action on the part of any holder thereof, each share of common stock of Relay, par value of $0.00001 per share, outstanding immediately prior to the Effective Date shall be changed and converted into one fully


- 3 -

paid and non-assessable share of the common stock of the Surviving Corporation, par value of $0.00001 per share (the "Survivor Stock").

2.2                 Relay Sub Common Stock

                      Upon the Effective Date, by virtue of the Merger and without any action on the part of the shareholder thereof, each share of common stock of the Relay Sub outstanding immediately prior to the Effective Date shall be cancelled.

2.3                 Exchange of Certificates

                      Each person who becomes entitled to receive any Survivor Stock by virtue of the Merger shall be entitled to receive from the Surviving Corporation a certificate or certificates representing the number of Survivor Stock to which such person is entitled as provided herein.

3.                  EFFECT OF THE MERGER

3.1                Rights, Privileges, Etc.

                      On the Effective Date of the Merger, the Surviving Corporation, without further act, deed or other transfer, shall retain or succeed to, as the case may be, and possess and be vested with all the rights, privileges, immunities, powers, franchises and authority, of a public as well as of a private nature, of Relay Sub and Relay; all property of every description and every interest therein, and all debts and other obligations of or belonging to or due to each of Relay Sub and Relay on whatever account shall thereafter be taken and deemed to be held by or transferred to, as the case may be, or invested in the Surviving Corporation without further act or deed, title to any real estate, or any interest therein vested in Relay Sub or Relay, shall not revert or in any way be impaired by reason of this merger; and all of the rights of creditors of Relay Sub and Relay shall be preserved unimpaired, and all liens upon the property of Relay Sub or Relay shall be preserved unimpaired, and all debts, liabilities, obligations and duties of the respective corporations shall thenceforth remain with or be attached to, as the case may be, the Surviving Corporation and may be enforced against it to the same extent as if all of said debts, liabilities, obligations and duties had been incurred or contracted by it.

3.2                 Further Assurances

                      From time to time, as and when required by the Surviving Corporation or by its successors and assigns, there shall be executed and delivered on behalf of Relay Sub such deeds and other instruments, and there shall be taken or caused to be taken by it such further other action, as shall be appropriate or necessary in order to vest or perfect in or to confirm of record or otherwise in the Surviving Corporation the title to and possession of all the property, interest, assets, rights, privileges, immunities, powers, franchises and authority of Relay Sub and otherwise to carry out the purposes of this Agreement, and the officers and directors of the Surviving Corporation are fully authorized in the name and on behalf of Relay Sub or otherwise to take any and all such action and to execute and deliver any and all such deeds and other instruments.


- 4 -

4.                  GENERAL

4.1                 Abandonment  

                      At any time before the Effective Date, this Agreement may be terminated and the Merger may be abandoned for any reason whatsoever by the Board of Directors of either Relay Sub or Relay or both. 

4.2                Amendment  

                      At any time prior to the Effective Date, this Agreement may be amended or modified in writing by the Board of Directors of either Relay Sub or Relay or both.

4.3                Governing Law  

                      This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Nevada and the merger provisions of the Nevada Revised Statutes.

4.4                 Counterparts

                      In order to facilitate the filing and recording of this Agreement, the same may be executed in any number of counterparts, each of which shall be deemed to be an original.

4.5                 Electronic Means

                      Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Agreement as of the date hereof.

IN WITNESS WHEREOF , the parties hereto have entered into and signed this Agreement as of the date and year first written.

  RELAY MINES LIMITED
     
     
  Per: /s/ Logan B. Anderson  
    Name: Logan B. Anderson 
    Title: President and Director 
     
     
  TSI MED ACQUISITION CORP.  
     
     
  Per: /s/ Reg C. Handford
    Name: Reg C. Handford 
    Title: President and Director 

 




DEAN HELLER
Secretary of State

204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz

FILED # C2820-01

SEP 13 2004

IN THE OFFICE OF
Dean Heller
DEAN HELLER, SECRETARY OF STATE


Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 1

Important: Read attached instructions before completing form.

ABOVE SPACE IS FOR OFFICE USE ONLY

(Pursuant to Nevada Revised Statutes Chapter 92A)
(excluding 92A.200(4b))

SUBMIT IN DUPLICATE

  1) Name and jurisdiction of organization of each constituent entity (NRS 92A.200). If there are more than four merging entities, check box   ¨   and attach an 81/2" x 11'' blank sheet containing the required information for each additional entity.
         
    TSI MED ACQUISITION CORP. 
         
    Name of merging entity      
         
    NEVADA    CORPORATION 
    Jurisdiction    Entity type * 
         
     
         
    Name of merging entity      
         
         
    Jurisdiction    Entity type * 
         
     
         
    Name of merging entity      
         
         
    Jurisdiction    Entity type * 
         
     
         
    Name of merging entity      
         
         
    Jurisdiction    Entity type * 
         
    and,     
         
         
    RELAY MINES LIMITED     
         
    Name of surviving entity      
         
    NEVADA    CORPORATION 
    Jurisdiction    Entity type * 

* Corporation, non-profit corporation, limited partnership, limited-liability company or business trust.

This form must be accompanied by appropriate fees. See attached fee schedule.   Nevada Secretary of State AM Merger 2003  
  Revised on: 10/24/03  




DEAN HELLER
Secretary of State

204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz


Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 2

Important: Read attached instructions before completing form.

ABOVE SPACE IS FOR OFFICE USE ONLY

  2) Forwarding address where copies of process may be sent by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger - NRS 92A.1 90):  
         
         
     Attn:     
         
     c/o: 

 

 

 

 

  3) (Choose one)  
       
    ¨       The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.200).  
                         
    x       The undersigned declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180)  
                         
  4) Owner's approval (NRS 92A.200)(options a, b, or c must be used, as applicable, for each entity) (if there are more than four merging entities, check box    ¨   and attach an 8 1/2" x 11'' blank sheet containing the required information for each additional entity):
       
    (a) Owner's approval was not required from  
       
      TSI MED ACQUISITION CORP. 
      Name of merging entity, if applicable  
       
       
      Name of merging entity, if applicable  
       
       
      Name of merging entity, if applicable  
       
       
      Name of merging entity, if applicable  
       
      and, or;  
       
      RELAY MINES LIMITED 
      Name of surviving entity, if applicable  

This form must be accompanied by appropriate fees. See attached fee schedule.   Nevada Secretary of State AM Merger 2003  
  Revised on: 10/24/03  




DEAN HELLER
Secretary of State

204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz


Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 3

Important: Read attached instructions before completing form.

ABOVE SPACE IS FOR OFFICE USE ONLY

    (b) The plan was approved by the required consent of the owners of *: 
       
       
      Name of merging entity, if applicable 
       
       
      Name of merging entity, if applicable 
       
       
      Name of merging entity, if applicable 
       
       
      Name of merging entity, if applicable 
       
      and, or; 
       
       
      Name of surviving entity, if applicable 

* Unless otherwise provided in the certificate of trust or governing instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.

This form must be accompanied by appropriate fees. See attached fee schedule.   Nevada Secretary of State AM Merger 2003  
  Revised on: 10/24/03  




DEAN HELLER
Secretary of State

204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz


Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 4

Important: Read attached instructions before completing form.

ABOVE SPACE IS FOR OFFICE USE ONLY

    (c) Approval of plan of merger for Nevada non-profit corporation (NRS 92A.160): 
       
     
The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.
       
      TSI MED ACQUISITION CORP. 
      Name of merging entity, if applicable  
       
       
      Name of merging entity, if applicable  
       
       
      Name of merging entity, if applicable  
       
       
      Name of merging entity, if applicable  
      and, or; 
       
      RELAY MINES LIMITED 
      Name of surviving entity, if applicable  

This form must be accompanied by appropriate fees. See attached fee schedule.   Nevada Secretary of State AM Merger 2003  
  Revised on: 10/24/03  




DEAN HELLER
Secretary of State

204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz


Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 5

Important: Read attached instructions before completing form.

ABOVE SPACE IS FOR OFFICE USE ONLY

  5) Amendments, if any, to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200)*:  
     
   

Article 1.
The name of the corporation is XLR Medical Corp. 

 

 

 

 

     
  6) Location of Plan of Merger (check a or b):  
     
    ¨       (a) The entire plan of merger is attached; 
    or, 
     
    x       (b) The entire plan of merger is on file at the registered office of the surviving corporation, limited-liability company or business trust, or at the records office 
            address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200). 

 

    7) Effective date (optional)": 9/15/04   

* Amended and restated articles may be attached as an exhibit or integrated into the articles of merger. Please entitle them ''Restated'' or ''Amended and Restated,'' accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent - Nevada parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the surviving entity may be changed.

** A merger takes effect upon filing the articles of merger or upon a later date as specified in the articles, which must not be more than 90 days after the articles are filed (NRS 92A.240).

This form must be accompanied by appropriate fees. See attached fee schedule.   Nevada Secretary of State AM Merger 2003  
  Revised on: 10/24/03  




DEAN HELLER
Secretary of State

204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz


Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 6

Important: Read attached instructions before completing form.

ABOVE SPACE IS FOR OFFICE USE ONLY

  8)

Signatures - Must be signed by: An officer of each Nevada corporation; All general partners of each Nevada limited partnership; All general partners of each Nevada limited partnership; A manager of each Nevada limited-liability company with managers or all the members if there are no managers; A trustee of each Nevada business trust (NRS 92A.230)*

(if there are more than four merging entities, check box   ¨   and attach an 8 %'' x 1 1 '' blank       sheet containing the required information for each additional entity.):

                   
    TSI MED ACQUISITION CORP.   
    Name of merging entity                
        President    Sept. 13, 2004
    /s/ Reg Handford
    Signature     Title         Date    
                   
       
    Name of merging entity                
     
                   
    Signature     Title         Date    
                   
       
    Name of merging entity                
     
                   
    Signature     Title         Date    
                   
       
    Name of merging entity                
     
                   
    Signature     Title         Date    
                   
    RELAY MINES LIMITED   
    Name of surviving entity                
        President    Sept. 13, 2004
    /s/ Logan Anderson
    Signature     Title         Date    

* The articles of merger must be signed by each foreign constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this page or as an attachment, as needed.

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

This form must be accompanied by appropriate fees. See attached fee schedule.   Nevada Secretary of State AM Merger 2003  
  Revised on: 10/24/03  

Reset    


STATE OF NEVADA
Secretary of State
I hereby certify that this is a true and
complete copy of the document as filed
in this office

SEP 13 2004

Dean Heller

By /s/ Dean Heller



BYLAWS,
AS AMENDED

OF
RELAY MINES LIMITED

(A NEVADA CORPORATION)

ARTICLE I

OFFICES

                     Section 1. Registered Office . The registered office of Relay Mines Limited (the "Corporation") in the State of Nevada shall be in the City of Las Vegas or the City of Reno, State of Nevada.

                     Section 2. Other Offices. The Corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Nevada as the Board of Directors may from time to time determine or the business of the Corporation may require.

ARTICLE II

CORPORATE SEAL

                     Section 3. Corporate Seal. The corporate seal shall consist of a die bearing the name of the Corporation and the inscription, "Corporate Seal-Nevada." Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

ARTICLE III

STOCKHOLDERS' MEETINGS

                     Section 4. Place of Meetings. Meetings of the stockholders of the Corporation shall be held at such place, either within or without the State of Nevada, as may be designated from time to time by the Board of Directors, or, if not so designated, then at the office of the Corporation required to be maintained pursuant to Section 2 hereof.

1


                    Section 5. Annual Meeting.

                    (a) The annual meeting of the stockholders of the Corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors.

                    (b) At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be: (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (B) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (C) otherwise properly brought before the meeting by a stockholder. For business to be properly brought before an annual meeting by a stockholder, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation. To be timely, a stockholder's notice must be delivered to or mailed and received at the principal executive offices of the Corporation not later than the close of business on the sixtieth (60th) day nor earlier than the close of business on the ninetieth (90th) day prior to the first anniversary of the preceding year's annual meeting; provided, however, that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the date contemplated at the time of the previous year's proxy statement, notice by the stockholder to be timely must be so received not earlier than the close of business on the ninetieth (90th) day prior to such annual meeting and not later than the close of business on the later of the sixtieth (60th) day prior to such annual meeting or, in the event public announcement of the date of such annual meeting is first made by the Corporation fewer than seventy (70) days prior to the date of such annual meeting, the close of business on the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the Corporation. A stockholder's notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting: (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (ii) the name and address, as they appear on the Corporation's books, of the stockholder proposing such business, (iii) the class and number of shares of the Corporation which are beneficially owned by the stockholder, (iv) any material interest of the stockholder in such business and (v) any other information that is required to be provided by the stockholder pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the "1934 Act"), in his capacity as a proponent to a stockholder proposal. Notwithstanding the foregoing, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholder's meeting, stockholders must provide notice as required by the regulations promulgated under the 1934 Act. Notwithstanding anything in these Bylaws to the contrary, no business shall be conducted at any annual meeting except in accordance with the procedures set forth in this paragraph (b). The chairman of the annual meeting shall, if the facts warrant, determine and declare at the meeting that business was not properly brought before the meeting and in accordance with the provisions of this paragraph (b), and, if he should so determine, he shall so declare at the meeting that any such business not properly brought before the meeting shall not be transacted.

2


                    (c) Only persons who are confirmed in accordance with the procedures set forth in this paragraph (c) shall be eligible for election as directors. Nominations of persons for election to the Board of Directors of the Corporation may be made at a meeting of stockholders by or at the direction of the Board of Directors or by any stockholder of the Corporation entitled to vote in the election of directors at the meeting who complies with the notice procedures set forth in this paragraph (c). Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary of the Corporation in accordance with the provisions of paragraph (b) of this Section 5. Such stockholder's notice shall set forth (i) as to each person, if any, whom the stockholder proposes to nominate for election or re-election as a director: (A) the name, age, business address and residence address of such person, (B) the principal occupation or employment of such person, (c) the class and number of shares of the Corporation which are beneficially owned by such person, (D) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder, and (E) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the 1934 Act (including without limitation such person's written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected); and (ii) as to such stockholder giving notice, the information required to be provided pursuant to paragraph (b) of this Section 5. At the request of the Board of Directors, any person nominated by a stockholder for election as a director shall furnish to the Secretary of the Corporation that information required to be set forth in the stockholder's notice of nomination which pertains to the nominee. No person shall be eligible for election as a director of the Corporation unless nominated in accordance with the procedures set forth in this paragraph (c). The chairman of the meeting shall, if the facts warrant, determine and declare at the meeting that a nomination was not made in accordance with the procedures prescribed by these Bylaws, and if he should so determine, he shall so declare at the meeting, and the defective nomination shall be disregarded.

                    (d) For purposes of this Section 5, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

                    Section 6. Special Meetings.

                    (a) Special meetings of the stockholders of the Corporation may be called, for any purpose or purposes, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption), and shall be held at such place, on such date, and at such time as the Board of Directors, shall determine.

3


                    (b) If a special meeting is called by any person or persons other than the Board of Directors, the request shall be in writing, specifying the general nature of the business proposed to be transacted, and shall be delivered personally or sent by registered mail or by telegraphic or other facsimile transmission to the Chairman of the Board of Directors, the Chief Executive Officer, or the Secretary of the Corporation. No business may be transacted at such special meeting otherwise than specified in such notice. The Board of Directors shall determine the time and place of such special meeting, which shall be held not less than thirty-five (35) nor more than one hundred twenty (120) days after the date of the receipt of the request. Upon determination of the time and place of the meeting, the officer receiving the request shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of Section 7 of these Bylaws. If the notice is not given within sixty (60) days after the receipt of the request, the person or persons requesting the meeting may set the time and place of the meeting and give the notice. Nothing contained in this paragraph (b) shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board of Directors may be held.

                     Section 7. Notice of Meetings. Except as otherwise provided by law or the Articles of Incorporation, written notice of each meeting of stockholders shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, date and hour and purpose or purposes of the meeting. Notice of the time, place and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.

                     Section 8. Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the Articles of Incorporation, or by these Bylaws, the presence, in person or by proxy duly authorized, of the holder or holders of not less than one percent (1%) of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by law, the Articles of Incorporation or these Bylaws, all action taken by the holders of a majority of the votes cast, excluding abstentions, at any meeting at which a quorum is present shall be valid and binding upon the Corporation; provided, however, that directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Where a separate vote by a class or classes or series

4


is required, except where otherwise provided by the statute or by the Articles of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter and, except where otherwise provided by the statute or by the Articles of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of the votes cast, including abstentions, by the holders of shares of such class or classes or series shall be the act of such class or classes or series.

                     Section 9. Adjournment and Notice of Adjourned Meetings. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares casting votes, excluding abstentions. When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

                     Section 10. Voting Rights. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the Corporation on the record date, as provided in Section 12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person or by an agent or agents authorized by a proxy granted in accordance with Nevada law. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3) years from its date of creation unless the proxy provides for a longer period.

                     Section 11. Joint Owners of Stock. If shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a) if only one (1) votes, his act binds all; (b) if more than one (1) votes, the act of the majority so voting binds all; (c) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Nevada Court of Chancery for relief as provided in the General Corporation Law of Nevada, Section 217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection (c) shall be a majority or even-split in interest.

                     Section 12. List of Stockholders. The Secretary shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the

5


address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not specified, at the place where the meeting is to be held. The list shall be produced and kept at the time and place of meeting during the whole time thereof and may be inspected by any stockholder who is present.

                     Section 13. Action Without Meeting. No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, or by the written consent of the shareholders in accordance with Chapter 78 of the Nevada Revised Statutes.

                    Section 14. Organization.

                    (a) At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.

                    (b) The Board of Directors of the Corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the Corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.

ARTICLE IV

DIRECTORS

                     Section 15. Number and Qualification. The authorized number of directors of the Corporation shall be not less than one (1) nor more than twelve (12) as fixed from time

6


to time by resolution of the Board of Directors; provided that no decrease in the number of directors shall shorten the term of any incumbent directors. Directors need not be stockholders unless so required by the Articles of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws.

                     Section 16. Powers. The powers of the Corporation shall be exercised, its business conducted and its property controlled by the Board of Directors, except as may be otherwise provided by statute or by the Articles of Incorporation.

                     Section 17. Election and Term of Office of Directors. Members of the Board of Directors shall hold office for the terms specified in the Articles of Incorporation, as it may be amended from time to time, and until their successors have been elected as provided in the Articles of Incorporation.

                     Section 18. Vacancies. Unless otherwise provided in the Articles of Incorporation, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholder vote, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director's successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director.

                     Section 19. Resignation. Any director may resign at any time by delivering his written resignation to the Secretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors. If no such specification is made, it shall be deemed effective at the pleasure of the Board of Directors. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor shall have been duly elected and qualified.

                     Section 20. Removal. Subject to the Articles of Incorporation, any director may be removed by:

                    (a) the affirmative vote of the holders of a majority of the outstanding shares of the Corporation then entitled to vote, with or without cause; or

7


                    (b) the affirmative and unanimous vote of a majority of the directors of the Corporation, with the exception of the vote of the directors to be removed, with or without cause.

                    Section 21. Meetings.

                    (a) Annual Meetings. The annual meeting of the Board of Directors shall be held immediately after the annual meeting of stockholders and at the place where such meeting is held. No notice of an annual meeting of the Board of Directors shall be necessary and such meeting shall be held for the purpose of electing officers and transacting such other business as may lawfully come before it.

                    (b) Regular Meetings. Except as hereinafter otherwise provided, regular meetings of the Board of Directors shall be held in the office of the Corporation required to be maintained pursuant to Section 2 hereof. Unless otherwise restricted by the Articles of Incorporation, regular meetings of the Board of Directors may also be held at any place within or without the state of Nevada which has been designated by resolution of the Board of Directors or the written consent of all directors.

                    (c) Special Meetings. Unless otherwise restricted by the Articles of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Nevada whenever called by the Chairman of the Board, the President or any two of the directors.

                    (d) Telephone Meetings. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.

                    (e) Notice of Meetings. Notice of the time and place of all special meetings of the Board of Directors shall be orally or in writing, by telephone, facsimile, telegraph or telex, during normal business hours, at least twenty-four (24) hours before the date and time of the meeting, or sent in writing to each director by first class mail, charges prepaid, at least three (3) days before the date of the meeting. Notice of any meeting may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

                    (f) Waiver of Notice. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present shall sign a written waiver of notice. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting.

8


                    Section 22. Quorum and Voting.

                    (a) Unless the Articles of Incorporation requires a greater number and except with respect to indemnification questions arising under Section 43 hereof, for which a quorum shall be one-third of the exact number of directors fixed from time to time in accordance with the Articles of Incorporation, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Articles of Incorporation provided, however, at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.

                    (b) At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Articles of Incorporation or these Bylaws.

                     Section 23. Action Without Meeting. Unless otherwise restricted by the Articles of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing, and such writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.

                     Section 24. Fees and Compensation. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.

                    Section 25. Committees.

                    (a) Executive Committee. The Board of Directors may by resolution passed by a majority of the whole Board of Directors appoint an Executive Committee to consist of one (1) or more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, including without limitation the power or authority to declare a dividend, to authorize the issuance of stock and to adopt a certificate of ownership and merger, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to amending the Articles of Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board of Directors fix the designations and any of the preferences or

9


rights of such shares relating to dividends, redemption, dissolution, any distribution of assets of the Corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the Corporation or fix the number of shares of any series of stock or authorize the increase or decrease of the shares of any series), adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the Corporation's property and assets, recommending to the stockholders a dissolution of the Corporation or a revocation of a dissolution, or amending the bylaws of the Corporation.

                    (b) Other Committees. The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, from time to time appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one (1) or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall such committee have the powers denied to the Executive Committee in these Bylaws.

                    (c) Term. Each member of a committee of the Board of Directors shall serve a term on the committee coexistent with such member's term on the Board of Directors. The Board of Directors, subject to the provisions of subsections (a) or (b) of this Bylaw may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.

                    (d) Meetings. Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section 25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon written notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of written notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time before or after the meeting and will be

10


waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. A majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.

                     Section 26. Organization. At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or if the President is absent, the most senior Vice President, or, in the absence of any such officer, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.

ARTICLE V

OFFICERS

                     Section 27. Officers Designated. The officers of the Corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer, the Treasurer, the Controller, all of whom shall be elected at the annual organizational meeting of the Board of Direction. The Board of Directors may also appoint one or more Assistant Secretaries, Assistant Treasurers, Assistant Controllers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the Corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the Corporation shall be fixed by or in the manner designated by the Board of Directors.

                    Section 28. Tenure and Duties of Officers.

                    (a) General. All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors.

                    (b) Duties of Chairman of the Board of Directors. The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. If there is no President, then the Chairman of the Board of Directors shall also serve as the Chief Executive Officer of

11


the Corporation and shall have the powers and duties prescribed in paragraph (c) of this Section 28.

                    (c) Duties of President. The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors has been appointed and is present. Unless some other officer has been elected Chief Executive Officer of the Corporation, the President shall be the chief executive officer of the Corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the Corporation. The President shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time.

                    (d) Duties of Vice Presidents. The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

                    (e) Duties of Secretary. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the Corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties given him in these Bylaws and other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The President may direct any Assistant Secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

                    (f) Duties of Chief Financial Officer. The Chief Financial Officer shall keep or cause to be kept the books of account of the Corporation in a thorough and proper manner and shall render statements of the financial affairs of the Corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the Corporation. The Chief Financial Officer shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. The President may direct the Treasurer or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

12


                     Section 29. Delegation of Authority. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.

                     Section 30. Resignations. Any officer may resign at any time by giving written notice to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the Corporation under any contract with the resigning officer.

                     Section 31. Removal. Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or superior officers upon whom such power of removal may have been conferred by the Board of Directors.

ARTICLE VI

EXECUTION OF CORPORATE INSTRUMENTS AND VOTING
OF SECURITIES OWNED BY THE CORPORATION

                     Section 32. Execution of Corporate Instrument. The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the Corporation any corporate instrument or document, or to sign on behalf of the Corporation the corporate name without limitation, or to enter into contracts on behalf of the Corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the Corporation.

                    Unless otherwise specifically determined by the Board of Directors or otherwise required by law, promissory notes, deeds of trust, mortgages and other evidences of indebtedness of the Corporation, and other corporate instruments or documents requiring the corporate seal, and certificates of shares of stock owned by the Corporation, shall be executed, signed or endorsed by the Chairman of the Board of Directors, or the President or any Vice President, and by the Secretary or Treasurer or any Assistant Secretary or Assistant Treasurer. All other instruments and documents requiting the corporate signature, but not requiring the corporate seal, may be executed as aforesaid or in such other manner as may be directed by the Board of Directors.

                    All checks and drafts drawn on banks or other depositaries on funds to the credit of the Corporation or in special accounts of the Corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.

13


                    Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.

                     Section 33. Voting of Securities Owned by the Corporation. All stock and other securities of other corporations owned or held by the Corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President.

ARTICLE VII

SHARES OF STOCK

                     Section 34. Form and Execution of Certificates. Certificates for the shares of stock of the Corporation shall be in such form as is consistent with the Articles of Incorporation and applicable law. Every holder of stock in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairman of the Board of Directors, or the President or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the Corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. Each certificate shall state upon the face or back thereof, in full or in summary, all of the powers, designations, preferences, and rights, and the limitations or restrictions of the shares authorized to be issued or shall, except as otherwise required by law, set forth on the face or back a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional, or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this section or otherwise required by law or with respect to this section a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.

                     Section 35. Lost Certificates. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have

14


been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The Corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or his legal representative, to advertise the same in such manner as it shall require or to give the Corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.

                    Section 36. Transfers.

                    (a) Transfers of record of shares of stock of the Corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and upon the surrender of a properly endorsed certificate or certificates for a like number of shares.

                    (b) The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the General Corporation Law of Nevada.

                    Section 37. Fixing Record Dates.

                    (a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

                    (b) In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is filed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

15


                     Section 38. Registered Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Nevada.

ARTICLE VIII

OTHER SECURITIES OF THE CORPORATION

                     Section 39. Execution of Other Securities. All bonds, debentures and other corporate securities of the Corporation, other than stock certificates (covered in Section 34), may be signed by the Chairman of the Board of Directors, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the Corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the Corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the Corporation.

ARTICLE IX

DIVIDENDS

                     Section 40. Declaration of Dividends. Dividends upon the capital stock of the Corporation, subject to the provisions of the Articles of Incorporation, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Articles of Incorporation.

16


                     Section 41. Dividend Reserve. Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the Corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.

ARTICLE X

FISCAL YEAR

                     Section 42. Fiscal Year. The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors.

ARTICLE XI

INDEMNIFICATION

                     Section 43. Indemnification of Directors, Executive Officers, Other Officers, Employees and Other Agents.

                    (a) Directors Officers. The Corporation shall indemnify its directors and officers to the fullest extent not prohibited by the Nevada General Corporation Law; provided, however, that the Corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided, further, that the Corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the Corporation, (iii) such indemnification is provided by the Corporation, in its sole discretion, pursuant to the powers vested in the Corporation under the Nevada General Corporation Law or (iv) such indemnification is required to be made under subsection (d).

                    (b) Employees and Other Agents. The Corporation shall have power to indemnify its employees and other agents as set forth in the Nevada General Corporation Law.

                    (c) Expense. The Corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer, of the Corporation, or is or was serving at the request of the Corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer in connection with such proceeding upon receipt of an undertaking by or on behalf

17


of such person to repay said mounts if it should be determined ultimately that such person is not entitled to be indemnified under this Bylaw or otherwise.

                    Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e) of this Bylaw, no advance shall be made by the Corporation to an officer of the Corporation (except by reason of the fact that such officer is or was a director of the Corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to the proceeding, or (ii) if such quorum is not obtainable, or, even if obtainable, a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Corporation.

                    (d) Enforcement. Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the Corporation and the director or officer. Any right to indemnification or advances granted by this Bylaw to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. The claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting his claim. In connection with any claim for indemnification, the Corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standard of conduct that make it permissible under the Nevada General Corporation Law for the Corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the Corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the Corporation) for advances, the Corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed in the best interests of the Corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct set forth in the Nevada General Corporation Law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that

18


the director or officer is not entitled to be indemnified, or to such advancement of expenses, under this Article XI or otherwise shall be on the Corporation.

                    (e) Non-Exclusivity of Rights. The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any statute, provision of the Articles of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding office. The Corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the Nevada General Corporation Law.

                    (f) Survival of Rights. The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director, officer, employee or other agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

                    (g) Insurance. To the fullest extent permitted by the Nevada General Corporation Law, the Corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Bylaw.

                    (h) Amendments. Any repeal or modification of this Bylaw shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the Corporation.

                    (i) Saving Clause. If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Bylaw that shall not have been invalidated, or by any other applicable law.

                    (j) Certain Definitions. For the purposes of this Bylaw, the following definitions shall apply:

                    (i) The term "proceeding" shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.

                    (ii) The term "expenses" shall be broadly construed and shall include, without limitation, court costs, attorneys' fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding.

                    (iii) The term the "Corporation" shall include, in addition to the resulting Corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had

19


continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent or another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Bylaw with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued.

                    (iv) References to a "director," "executive officer," "officer," "employee," or "agent" of the Corporation shall include, without limitation, situations where such person is serving at the request of the Corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise.

                    (v) References to "other enterprises" shall include employee benefit plans; references to "fines" shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to "serving at the request of the Corporation" shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the Corporation" as referred to in this Bylaw.

ARTICLE XII

NOTICES

                    Section 44. Notices.

                    (a) Notice to Stockholders. Whenever, under any provisions of these Bylaws, notice is required to be given to any stockholder, it shall be given in writing, timely and duly deposited in the United States mail, postage prepaid, and addressed to his last known post office address as shown by the stock record of the Corporation or its transfer agent.

                    (b) Notice to directors. Any notice required to be given to any director may be given by the method stated in subsection (a), or by facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director.

                    (c) Affidavit of Mailing. An affidavit of mailing, executed by a duly authorized and competent employee of the Corporation or its transfer agent appointed with respect to the class of stock affected, specifying the name and address or the names and addresses

20


of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.

                    (d) Time Notices Deemed Given. All notices given by mail, as above provided, shall be deemed to have been given as at the time of mailing, and all notices given by facsimile, telex or telegram shall be deemed to have been given as of the sending time recorded at time of transmission.

                    (e) Methods of Notice. It shall not be necessary that the same method of giving notice be employed in respect of all directors, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others.

                    (f) Failure to Receive Notice. The period or limitation of time within which any stockholder may exercise any option or right, or enjoy any privilege or benefit, or be required to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent him in the manner above provided, shall not be affected or extended in any manner by the failure of such stockholder or such director to receive such notice.

                    (g) Notice to Person with Whom Communication Is Unlawful. Whenever notice is required to be given, under any provision of law or of the Articles of Incorporation or Bylaws of the Corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be require and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Corporation is such as to require the filing of a certificate under any provision of the Nevada General Corporation Law, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.

                    (h) Notice to Person with Undeliverable Address. Whenever notice is required to be given, under any provision of law or the Articles of Incorporation or Bylaws of the Corporation, to any stockholder to whom (i) notice of two consecutive annual meetings, and all notices of meetings or of the taking of action by written consent without a meeting to such person during the period between such two consecutive annual meetings, or (ii) all, and at least two, payments (if sent by first class mail) of dividends or interest on securities during a twelve-month period, have been mailed addressed to such person at his address as shown on the records of the Corporation and have been returned undeliverable, the giving of such notice to such person shall not be required. Any action or meeting which shall be taken or held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such person shall deliver to the Corporation a written notice setting forth his then current address, the requirement that notice be given to such person shall be reinstated. In the event that the action taken by the Corporation is

21


such as to require the filing of a certificate under any provision of the Nevada General Corporation Law, the certificate need not state that notice was not given to persons to whom notice was not required to be given pursuant to this paragraph.

ARTICLE XIII

AMENDMENTS

                    Section 45. Amendments.

                    The Board of Directors shall have the power to adopt, amend, or repeal Bylaws.

ARTICLE XIV

LOANS TO OFFICERS

                     Section 46. Loans to Officers. The Corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the Corporation or of its subsidiaries, including any officer or employee who is a Director of the Corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the Corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the Corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the Corporation at common law or under any statute.

Declared as the By-Laws, as amended, of Relay Mines Limited as of the 12th day of September, 2004.

Signature of Officer:  /s/ Carlo Civelli    
   
Name of Officer:  CARLO CIVELLI    
     
Position of Officer:  PRESIDENT   

22



TECHNOLOGY ACQUISITION AND FUNDING AGREEMENT

THIS AGREEMENT is dated for reference as of the 22 day of March, 2004.

BETWEEN:

TSI MEDICAL CORP.
a Nevada corporation
("TSI")

OF THE FIRST PART

AND:

EXELAR CORPORATION ,
a Delaware corporation
("Exelar")

OF THE SECOND PART

AND:

EXELAR MEDICAL CORPORATION
a Nevada corporation
("OPCO")

OF THE THIRD PART

WHEREAS:

A.                Exelar has acquired and developed a technology utilizing super-conducting magnets to control therapeutic radiation doses delivered by photon linear accelerators (the "Technology").

B.                TSI is desirous of participating in the development and commercialization of the Technology by funding the acquisition and development of the Technology.

C.                Exelar and TSI have caused OPCO to be incorporated for the purposes of completing the development and commercialization of the Technology.

THE PARTIES HEREBY AGREE AS FOLLOWS :

ARTICLE 1.
DEFINITIONS

1.1   The following terms will have the following meanings for all purposes of this Agreement.
     
  (a)     
"Agreement" shall mean this Agreement and all schedules and amendments to this Agreement;
     
  (b)     
"Apparatus" means an apparatus for control of therapeutic radiation doses using superconducting magnets described in the Patents and that incorporates any of the Patents, the Know- how and/or the Intellectual Property;

Page 1 of 24



  (c)     
"Closing" means the closing of the Transactions described in paragraphs 2.2 and 3.1(a);
 
  (d)     
"Closing Date" means the 5th business day following the execution of this Agreement;
 
  (e)     
"Closing Documents" means the documents to be executed and/ or delivered by each respective party on Closing;
 
  (f)     
"Common Stock" means the common stock of OPCO, par value $0.001 per share;
 
  (g)     
"Employment Agreement" means the agreement attached hereto as Schedule F;
 
  (h)     
"Improvement" means any modification or variant of the Apparatus and the Invention, whether patentable or not, which, if manufactured, used, or sold, would fall within the scope of the Apparatus, the Invention or at least one claim of at least one of the Patents;
 
  (i)     
"Intellectual Property" means all copyrights, patent rights, trade secret rights, trade names, trademark rights, process information, technical information, designs, drawings, inventions and all other intellectual and industrial property rights of any sort related to or associated with Invention and the Apparatus;
 
  (j)     
"Invention" means the invention described in the Patents and embodied in the Apparatus";
 
  (k)     
"Inventor" means Len Reiffel.
 
  (l)     
"Know- how" means all know- how, knowledge, expertise, inventions, works of authorship, prototypes, technology, information, know- how, materials and tools relating thereto or to the design, development, manufacture, use and commercial application of the Invention and the Apparatus;
 
  (m)     
"Patents" means the Patents, patent applications and foreign patent applications described in Schedule A and any other patent that may be issued in connection with the Invention or the Apparatus or any Improvement;
 
  (n)     
"Promissory Note" means the Secured Promissory Note to be issued to the Inventor under the Technology Transfer Agreement
 
  (o)     
"Shareholders Agreement" means a unanimous shareholders agreement to be entered into between TSI and Exelar in the form attached hereto as Schedule D;
 
  (p)     
"Technology" means the Apparatus, the Invention, the Patents, the Know- How and the Intellectual Property;
 
  (q)     
Technology Transfer Agreement" means the agreement among OPCO, Exelar and the Inventor attached hereto as Schedule C;

Page 2 of 24



1.2   The following schedules are attached to and form part of this Agreement:

    Schedule A  Description of Patents 
       
    Schedule B  Intentionally Deleted 
       
    Schedule C  Technology Transfer Agreement 
       
    Schedule D  Shareholders Agreement 
       
    Schedule E  Budget 
       
    Schedule F  Employment Agreement 
       
1.3   All dollar amounts referred to in this agreement are in United States funds, unless expressly stated otherwise.

ARTICLE 2.
PURCHASE AND SALE OF TECHNOLOGY

2.1                                    Exelar has contributed, assigned and transferred the Technology to OPCO in exchange for and in consideration for OPCO assuming Exelar's obligations under the Promissory Note and Technology Transfer Agreement and the issuance to Exelar of 2,280,000 shares of OPCO's common stock, par value $0.001.

2.2                                    Exelar and OPCO will enter into, and Exelar will cause the Inventor to enter into, the Technology Transfer Agreement at closing.

ARTICLE 3.
FUNDING BY TSI

3.1                                    TSI agrees to provide cash in same day funds of U.S. Dollars to OPCO as follows:

 
(a)     
$325,000 (the "Initial Funding") at Closing;
 
 
(b)     
a further $4,425,000 (the "Post Closing Funding") in tranches as follows:
 
   
(i)     
$575,000 on or before the date that is 90 days following closing;
 
   
(ii)     
$1,550,000 on or before the date that is 180 days following closing;
 
   
(iii)     
$1,000,000 on or before the date that is 270 days following closing; and
 
   
(iv)     
$1,300,000 on or before the date that is 360 days following closing.
 
   
Any payments made by TSI to Exelar under the Promissory Note, whether to pay the obligations thereunder or cure defaults thereunder, shall be credited against TSI's Post - Closing Funding obligations.
 
3.2     
Subject to section 12 hereof, TSI shall be issued one common share of OPCO for each $2.00 of funding forthwith upon receipt of each tranche of funding.
 
3.3     
Notwithstanding the dates set forth in section 3.1(b) above, OPCO may request such dates to be accelerated, upon 10 days written notice to TSI, if OPCO provides written affirmation that it has specific uses for such funds which are consistent with the overall

Page 3 of 24



   
purposes and uses of those funds in the future, provided that TSI shall not be obligated to so accelerate. purposes and uses of those funds in the future, provided that TSI shall not be obligated to so accelerate. v

ARTICLE 4.
EXPENDITURE OF TSI FUNDING

               4.1                      OPCO agrees to expend the funds provided by TSI substantially in accordance with the budget attached as Schedule E to this Agreement (the "Budget"), with the understanding that changes may need to be made based on unexpected events and based on the evolution of the commercialization process. Nothing contained herein shall in any event change the payment schedule of the Promissory Note unless agreed to in writing by TSI and Exelar.

               4.2                      The board of directors of OPCO may make changes to the Budget as they deem necessary to the proper development and commercialization of the Technology provided that no changes shall be made that would prevent OPCO from being able to make payment of the Promissory Note when such notes are due.

ARTICLE 5.
TSI ADDITIONAL FUNDING OPTION

               5.1                       In the event that, following completion of the entire amounts contemplated by the Post-Closing Funding by TSI, the Board (as defined in the Shareholders Agreement) determines that additional funding is required to complete the development and commercialization of the Technology, TSI shall have the option to provide an additional $1,500,000 of funding (the TSI Additional Funding") in consideration of the issuance to TSI of such number of common shares of OPCO as shall, after their issuance, when aggregated with the shares of OPCO previously acquired by TSI, result in TSI holding 60% of the issued and outstanding shares of OPCO. It is understood that the 60% figure assumes that there has been no future issuances of common stock, or instruments convertible into stock (such as warrants or options). The right to infuse the TSI Additional Funding shall expire two (2) years from the initial closing. If the Board determines that all or a portion of such TSI Additional Funding is needed, but determines that such TSI Additional Funding may be obtained from other source(s) more expeditiously and/or at a lower cost, the Board need not extend such option to TSI.

               5.2                      TSI shall provide the TSI Additional Funding within 30 days following receipt of notice from OPCO that its board of directors have determined that the funding is required from TSI. or else the provisions of section 5.1 shall be terminated, null and void

ARTICLE 6.
EXELAR OPTION

               6.1                      Upon the first to occur of (a) the completion of the Post-Closing Funding by TSI, (b) a default by TSI in making any investment of Post-Closing Funding, (c) March 1, 2005 or (d) the initial public offering of shares of TSI or any subsidiary thereof (an "IPO"), and prior to any TSI Additional Funding, Exelar shall have the option, exercisable by written notice to TSI, to convert up to 100% of its shares of OPCO into such number of common shares or shares convertible into common shares of TSI as shall, after their issuance, represent 49% (the "Conversion Percentage") of the number of issued and outstanding common shares and shares, options and other debt and equity instruments convertible into common shares of TSI then outstanding on a fully-diluted basis (the "Exelar Put Option").

               6.2                      In the event that Exelar exercises the Exelar Put Option and at the time of such exercise TSI shall have any options or warrants outstanding, Exelar shall be entitled to be issued options and warrants exercisable at the same price and on the same terms as the outstanding options and warrants such that, assuming all outstanding warrants and options were exercised, would result in Exelar and its directors, officers and shareholders maintaining its 49% interest in the outstanding common shares of TSI.

Page 4 of 24


               6.3                      In the event that TSI (and its affiliates on a consolidated basis even if such affiliates are not actually consolidated) shall have current assets exceeding its current and long-term liabilities (as well as reasonable estimate of liabilities which are not recorded on the balance sheet of TSI) at the time Exelar exercises the Exelar Put Option, TSI will have the Option to distribute such excess to its existing securities holders prior to the issuance of its securities to Exelar. In the event that the difference in the preceding sentence is a negative number, then the Conversion Percentage shall be increased by 1% for every $43,750 which is negative (pro rated for partial percentages).

               6.4                      Prior to the exercise of the Exelar Put Option, (a) TSI shall make no dividends, distributions, spin-offs, split-offs or other sale, transfer or assignment of its stock in Techniscan Medical Systems, Inc. except that it may pledge the shares of Techniscan Medical Systems, Inc. in exchange for cash which will be used in part to fund the Purchase Price, (b) Exelar and its representatives and agents shall have the right to conduct a normal and complete due diligence of TSI and its subsidiaries and affiliates to fully and comprehensively understand TSI's business, assets, liabilities, financial condition and prospects and TSI shall provide normal and customary representations and warranties regarding TSI, its subsidiaries and affiliates and such information and (c) TSI shall keep Exelar informed regarding TSI's fundraising efforts and status, will give Exelar access to TSI and affiliates books and records, shareholder lists, financial statements and results of operations on a periodic basis, in a reasonable manner and so as not to be unduly burdensome or disruptive.

ARTICLE 7.
REPRESENTATIONS AND WARRANTIES OF EXELAR

Exelar represents and warrants to OPCO and TSI and acknowledges that OPCO and TSI are relying upon such representations and warranties in connection with the execution, delivery and performance of this Agreement.

               7.1                       Organization and Good Standing . Exelar is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.

               7.2                       Authority . Exelar has all requisite corporate power and authority to execute and deliver this Agreement and any other Closing Documents to be signed by it, to perform its obligations under this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and any other Closing Documents by Exelar and the consummation by Exelar of the transactions contemplated by this Agreement and any other Closing Documents have been duly authorized by its board of directors and no other corporate or shareholder proceedings on the part of Exelar are necessary to authorize such documents or to consummate the transactions contemplated thereby. This Agreement has been, and the Closing Documents when executed and delivered by Exelar as contemplated by this Agreement will be, duly executed and delivered by Exelar. This Agreement is and the Closing Documents will be valid and binding obligations of Exelar enforceable in accordance with their respective terms, except (1) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, and (2) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

               7.3                       Noncontravention . Neither the execution, delivery and performance of this Agreement or the Closing Documents, nor the consummation of the transactions contemplated by this Agreement, will:

              (1)                      Conflict with, result in a violation of, cause a default under (with or without notice, lapse of time or both) or give rise to a right of termination, amendment, cancellation or acceleration under any agreement to which Exelar is a party or by which the Technology are bound except for its obligations under that certain Subagreement No. 2000-106800-Exelar-Reiffel by and between National Medical Technology Testbed Inc. and Exelar (the "NMTB Agreement");

              (2)                      Violate any provision of the articles of incorporation or by-laws of Exelar; or

Page 5 of 24


              (3)                      Violate any order, writ, injunction, decree, statute, rule, or regulation of any court or governmental or regulatory authority applicable to Exelar or any of its respective property or assets.

               7.4                       Actions and Proceedings . There is no claim, charge, arbitration, grievance, action, suit, investigation or proceeding by or before any court, arbiter, administrative agency or other governmental authority now pending or, to the best knowledge of Exelar, threatened against Exelar which involves the Technology.

               7.5                       Compliance . Exelar is in compliance with, is not in default or violation in any material respect under, and has not been charged with or received any notice at any time of any material violation by it of, any statute, law, ordinance, regulation, rule, decree or other regulation applicable to the business or operations of Exelar.

               7.6                       Filings, Consents and Approvals . No filing or registration with, no notice to and no permit, authorization, consent, or approval of any public or governmental body or authority or other person or entity is necessary for the consummation by Exelar of the transactions contemplated by this Agreement and the Closing Documents.

               7.7                       Property . Exelar is the beneficial owner of the Technology free and clear of any liens, charges or encumbrances and no other person has any interest in the Technology except for the rights of the Inventor under the Promissory Note.

               7.8                      Exelar understands that all shares of OPCO's common stock issued by OPCO and any shares that may be issued of TSI under paragraph 6.2 pursuant to this Agreement (the "Shares") will be governed by the following:

    (1)     
All Shares will be issued as "restricted shares", as contemplated by the Securities Act of 1933 (the "1933 Act"). Exelar acknowledges and agrees that the Shares have not been registered under the 1933 Act or applicable state "Blue Sky" laws and, therefore, the Shares may not be resold, transferred or hypothecated without the registration of the Shares, or an opinion of counsel satisfactory to OPCO to the effect that such registration is not necessary;
 
    (2)     
All certificates representing the Shares will be endorsed with the following legend:
 
     
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT"), AND HAVE BEEN OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, TRANSFERRED, PLEDGED OR RESOLD OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER THE APPLICABLE PROVISIONS OF THE ACT OR ARE EXEMPT FROM SUCH REGISTRATION REQUIREMENTS." ;
 
    (3)     
All Shares will be issued to Exelar based on the representations and warranties of Exelar that:
 
     
(i)     
Exelar has not offered or sold the Shares within the meaning of the 1933 Act;
 
     
(ii)     
Exelar is acquiring the Shares for its own account for investment, with no present intention of dividing any interest with others or of reselling or otherwise disposing of all or any portion of the same;

Page 6 of 24



      (iii) 
Exelar does not intend any sale of the Shares either currently or after the passage of a fixed or determinable period of time or upon the occurrence or non-occurrence of any predetermined event or circumstance;
         
      (iv) 
Exelar has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for or which is likely to compel a disposition of the Shares;
         
      (r) 
Exelar is not aware of any circumstances presently in existence which are likely in the future to prompt a disposition of the Shares;
         
      (vi) 
The Shares were offered to Exelar in direct communication and not through any advertisement of any kind;
         
      (vii) 
Exelar has the financial means to bear the economic risk of an investment in the Shares.

ARTICLE 8.
REPRESENTATIONS AND WARRANTIES OF TSI

TSI represents and warrants to Exelar and OPCO and acknowledges that Exelar and OPCO are relying upon such representations and warranties in connection with the execution, delivery and performance of this Agreement.

               8.1                       Organization and Good Standing . TSI is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada.

               8.2                       Authority . TSI has all requisite corporate power and authority to execute and deliver this Agreement and any other Closing Documents to be signed by it, to perform its obligations under this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and any other Closing Documents by TSI and the consummation by TSI of the transactions contemplated by this Agreement and any other Closing Documents have been duly authorized by its board of directors and no other corporate or shareholder proceedings on the part of TSI are necessary to authorize such documents or to consummate the Transaction or the transactions contemplated thereby. This Agreement has been, and the Closing Documents when executed and delivered by TSI as contemplated by this Agreement will be, duly executed and delivered by TSI. This Agreement is and the Closing Documents will be valid and binding obligations of TSI enforceable in accordance with their respective terms, except (1) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, and (2) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. Neither TSI has nor any of its shareholders are parties to any shareholder agreement, voting trust agreement, voting agreement, proxy, or similar agreement regarding the voting of any shares of TSI or any affiliate thereof and shall not enter into any such agreement without Exelar's prior written approval.

               8.3                       Noncontravention . Neither the execution, delivery and performance of this Agreement or the Closing Documents, nor the consummation of the Transaction, will:

               (1)                      Conflict with, result in a violation of, cause a default under (with or without notice, lapse of time or both) or give rise to a right of termination, amendment, cancellation or acceleration under any agreement to which TSI is a party or by which its assets or properties are bound;

               (2)                      Violate any provision of the articles of incorporation or by-laws of TSI; or

Page 7 of 24


               (3)                      Violate any order, writ, injunction, decree, statute, rule, or regulation of any court or governmental or regulatory authority applicable to TSI or any of its respective property or assets.

               8.4                       Actions and Proceedings . There is no claim, charge, arbitration, grievance, action, suit, investigation or proceeding by or before any court, arbiter, administrative agency or other governmental authority now pending or, to the best knowledge of TSI, threatened against TSI which involves the Technology or its ability to provide the funding contemplated herein. TSI believes in good faith that it has access to the financing to timely fulfill its obligations under Article 3 hereof. TSI will use its best efforts to obtain the financing contemplated herein although it makes no guarantee that such financing will be obtained.

               8.5                       Compliance . TSI is in compliance with, is not in default or violation in any material respect under, and has not been charged with or received any notice at any time of any material violation by it of, any statute, law, ordinance, regulation, rule, decree or other regulation applicable to the business or operations of TSI. TSI and its affiliates and agents have complied with all Canadian, U.S. and state laws, rules and regulations in selling securities in TSI and raising funds which will be invested in OPCO pursuant to this Agreement.

               8.6                       Filings, Consents and Approvals . No filing or registration with, no notice to and no permit, authorization, consent, or approval of any public or governmental body or authority or other person or entity is necessary for the consummation by TSI of the transactions contemplated by this Agreement and the Closing Documents.

               8.7                      TSI acknowledges that all shares of OPCO's common stock issued by OPCO pursuant to this Agreement (the "Shares") will be governed by the following:

    (1)     
All Shares will be issued as "restricted shares", as contemplated by the Securities Act of 1933 (the "1933 Act"). Exelar acknowledges and agrees that the Shares have not been registered under the 1933 Act or applicable state "Blue Sky" laws and, therefore, the Shares may not be resold, transferred or hypothecated without the registration of the Shares, or an opinion of counsel satisfactory to OPCO to the effect that such registration is not necessary;
 
    (2)     
All certificates representing the Shares will be endorsed with the following legend:
 
     
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT"), AND HAVE BEEN OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, TRANSFERRED, PLEDGED OR RESOLD OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER THE APPLICABLE PROVISIONS OF THE ACT OR ARE EXEMPT FROM SUCH REGISTRATION REQUIREMENTS.";
 
    (3)     
All Shares will be issued to TSI based on the representations and warranties of Exelar that:
 
     
(i)     
TSI has not offered or sold the Shares within the meaning of the 1933 Act;
 
     
(ii)     
TSI is acquiring the Shares for its own account for investment, with no present intention of dividing any interest with others or of reselling or otherwise disposing of all or any portion of the same;

Page 8 of 24


      (i) 
TSI does not intend any sale of the Shares either currently or after the passage of a fixed or determinable period of time or upon the occurrence or non- occurrence of any predetermined event or circumstance;
         
      (ii) 
TSI has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for or which is likely to compel a disposition of the Shares;
         
      (b) 
TSI is not aware of any circumstances presently in existence which are likely in the future to prompt a disposition of the Shares;
         
      (vii) 
The Shares were offered to TSI in direct communication and not through any advertisement of any kind;
         
      (vii) 
TSI has the financial means to bear the economic risk of an investment in the Shares.


ARTICLE 9.
REPRESENTATIONS AND WARRANTIES OF OPCO

As of the date hereof, OPCO represents and warrants to the Investor and acknowledges that the Investor is relying upon such representations and warranties in connection with the execution, delivery and performance of this Agreement.

               9.1                       Organization and Good Standing . OPCO is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada contemplated by this Agreement.

               9.2                       Authority . OPCO has all requisite corporate power and authority to execute and deliver this Agreement and any other Closing Documents to be signed by it, to perform its obligations under this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and any other Closing Documents by OPCO and the consummation by OPCO of the transactions contemplated by this Agreement and any other Closing Documents have been duly authorized by its board of directors and no other corporate or shareholder proceedings on the part of OPCO are necessary to authorize such documents or to consummate the transactions contemplated thereby. This Agreement has been, and the Closing Documents when executed and delivered by OPCO as contemplated by this Agreement will be, duly executed and delivered by OPCO. This Agreement is and the Closing Documents will be valid and binding obligations of OPCO enforceable in accordance with their respective terms, except (1) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, and (2) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

                9.3                       Capitalization of OPCO . The entire authorized capital stock of OPCO consists of 100,000,000 shares of Common Stock, of which no shares are issued and outstanding. Except for this Agreement and the Shareholders Agreement, there are no outstanding options, warrants, subscriptions, conversion rights, or other rights, agreements, or commitments obligating OPCO to issue any additional shares of the Common Stock, or any other securities convertible into, exchangeable for, or evidencing the right to subscribe for or acquire from OPCO any shares of Common Stock. There are no agreements other than the Shareholders Agreement purporting to restrict the transfer of the Common Stock or affecting the voting of the outstanding shares of Common Stock.

               9.4                       Valid Issuance of Purchased Securities . The Shares to be issued as contemplated by this Agreement, when issued, sold, paid for and delivered in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and nonassessable and will be free from restrictions on transfer other than restrictions on transfer under this Agreement and the Shareholders Agreement and under applicable state and federal securities laws.

Page 9 of 24


               9.5                       Subsidiaries . OPCO does not have any subsidiaries as of the date hereof.

               9.6                       Noncontravention . Neither the execution, delivery and performance of this Agreement or the Closing Documents, nor the consummation of the Transaction, will:

               (1)                      Conflict with, result in a violation of, cause a default under (with or without notice, lapse of time or both) or give rise to a right of termination, amendment, cancellation or acceleration under any agreement to which OPCO is a party or by which its assets or properties are bound;

               (2)                      Violate any provision of the articles of incorporation or by-laws of OPCO; or

               (3)                      Violate any order, writ, injunction, decree, statute, rule, or regulation of any court or governmental or regulatory authority applicable to OPCO or any of its respective property or assets.

               9.7                       Actions and Proceedings . There is no claim, charge, arbitration, grievance, action, suit, investigation or proceeding by or before any court, arbiter, administrative agency or other governmental authority now pending or, to the best knowledge of OPCO, threatened against OPCO.

               9.8                       Compliance . OPCO is in compliance with, is not in default or violation in any material respect under, and has not been charged with or received any notice at any time of any material violation by it of, any statute, law, ordinance, regulation, rule, decree or other regulation applicable to the business or operations of OPCO.

               9.9                       Filings, Consents and Approvals . No filing or registration with, no notice to and no permit, authorization, consent, or approval of any public or governmental body or authority or other person or entity is necessary for the consummation by OPCO of the transactions contemplated by this Agreement and the Closing Documents except under the NMTB Agreement.

               9.10                      Real Property . OPCO does not own any real property.

               9.11                      Material Assets & Liabilities . OPCO does not have and will not have at Closing any material assets or liabilities other than those to be acquired by it under this Agreement and the other Closing Documents.

               9.12                      No Brokers . OPCO has not incurred any obligation or liability to any party for any brokerage fees, agent's commissions, or finder's fees in connection with the transactions contemplated by this Agreement.

               9.13                      Minute Books . The minute books of OPCO contain a complete summary of all meetings of directors and shareholders since the time of incorporation of such entity and reflect all transactions referred to in such minutes accurately in all material respects.

               9.14                      Completeness of Disclosure . No representation or warranty by OPCO in this Agreement nor any certificate, schedule, statement, document or instrument furnished or to be furnished pursuant hereto contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact required to be stated herein or therein or necessary to make any statement herein or therein not materially misleading.

ARTICLE 10.
CLOSING CONDITIONS

               10.1                      Conditions Precedent to Closing by Exelar . The obligation of Exelar to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the conditions set forth below in favour of Exelar, unless any such condition is waived by Exelar at the Closing.

Page 10 of 24


                              (a)                        Representations and Warranties . The representations and warranties of OPCO and TSI set forth in this Agreement will be true, correct and complete in all material respects as of the Closing Date, as though made on and as of the Closing Date.

                              (b)                        Performance . All of the covenants and obligations that OPCO and TSI are required to perform or to comply with pursuant to this Agreement at or prior to the Closing must have been performed and complied with in all material respects. OPCO and TSI must have delivered each of the documents required to be delivered by OPCO and TSI pursuant to this Agreement.

                              (c)                        Closing Documents . This Agreement and all Closing Documents to be executed by OPCO and TSI, as necessary or reasonably required to consummate the transactions contemplated by this Agreement in accordance with this Agreement, will have been executed and delivered to Exelar.

                              (d)                      Amendment to the NMTB Agreement . The NMTB Agreement shall have been amended to provide that NMTB:

                              (i)                      has no further rights under the NMTB Agreement including without limitation any rights to the T echnology, or to any equity in Exelar or OPCO, or to any royalties or rights to receive any fees, royalties, costs or expenses from Exelar or OPCO except as set froth in clauses (ii) and (iii) below;

                              (ii)                      OPCO shall pay NMTB the sum of $100,000 on or before the date that is ninety (90) days following the Closing; and

                              (iii)                    OPCO shall pay a royalty (the "Royalty") to NMTB equal to 3.5% of OPCO's Net Sales (as defined) from sales or licenses of any products (the "Products") sold or licensed by OPCO which Products have been directly made, used or sold as a result of the Technology. Notwithstanding the foregoing, the aggregate Royalty shall not exceed $1 million and all obligations hereunder shall terminate and be null and void when and if such sum has been received by NMTB or its successor or assigns. The Royalty shall be paid quarterly within 45 days after the end of the preceding calendar quarter. "Net Sales" shall mean gross sales from the Products less returns, allowances, shipping and handling, insurance, sales and related taxes, and similar deductions.

               10.2                      Conditions Precedent to Closing by TSI . The obligation of TSI to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the conditions set forth below in favour of TSI, unless any such condition is waived by TSI at the Closing.

                              (a)                        Representations and Warranties . The representations and warranties of Exelar and OPCO set forth in this Agreement will be true, correct and complete in all material respects as of the Closing Date, as though made on and as of the Closing Date.

                              (b)                      Performance . All of the covenants and obligations that Exelar and OPCO are required to perform or to comply with pursuant to this Agreement at or prior to the Closing must have been performed and complied with in all material respects. Exelar and OPCO must have delivered each of the documents required to be delivered by Exelar and OPCO pursuant to this Agreement

                              (c)                      Closing Documents . This Agreement and all Closing Documents to be executed by Exelar, OPCO and the Inventor, as necessary or reasonably required to consummate the transactions contemplated by this Agreement in accordance with this Agreement, will have been executed and delivered to TSI.

                              (d)                      Amendment to the NMTB Agreement . The NMTB Agreement shall have been amended to provide that NMTB:

Page 11 of 24


                              (i)                      has no further rights under the NMTB Agreement including without limitation any rights to the Technology, or to any equity in Exelar or OPCO, or to any royalties or rights to receive any fees, royalties, costs or expenses from Exelar or OPCO except as set froth in clauses (ii) and (iii) below;

                              (ii)                     OPCO shall pay NMTB the sum of $100,000 on or before the date that is ninety (90) days following the Closing; and

                              (iii)                     OPCO shall pay a royalty (the "Royalty") to NMTB equal to 3.5% of OPCO's Net Sales (as defined) from sales or licenses of any products (the "Products") sold or licensed by OPCO which Products have been directly made, used or sold as a result of the Technology. Notwithstanding the foregoing, the aggregate Royalty shall not exceed $1 million and all obligations hereunder shall terminate and be null and void when and if such sum has been received by NMTB or its successor or assigns. The Royalty shall be paid quarterly within 45 days after the end of the preceding calendar quarter. "Net Sales" shall mean gross sales from the Products less returns, allowances, shipping and handling, insurance, sales and related taxes, and similar deductions.

               10.3                      Conditions Precedent to Closing by OPCO . The obligation of OPCO to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the conditions set forth below in favour of OPCO, unless any such condition is waived by OPCO at the Closing.

                              (a)                      Representations and Warranties . The representations and warranties of Exelar and TSI set forth in this Agreement will be true, correct and complete in all material respects as of the Closing Date, as though made on and as of the Closing Date.

                              (b)                      Performance . All of the covenants and obligations that Exelar and TSI are required to perform or to comply with pursuant to this Agreement at or prior to the Closing must have been performed and complied with in all material respects. Exelar and TSI must have delivered each of the documents required to be delivered by Exelar and TSI pursuant to this Agreement

                              (c)                      Closing Documents . This Agreement and all Closing Documents to be executed by Exelar, TSI and the Inventor, as necessary or reasonably required to consummate the transactions contemplated by this Agreement in accordance with this Agreement, will have been executed and delivered to OPCO.

ARTICLE 11.
CLOSING

               11.1                      Closing . The Closing shall take place on the Closing Date at the offices of OPCO or at such other location as agreed to by the parties (or by fax, mail or other means). Notwithstanding the location of the Closing, each party agrees that the Closing may completed by the exchange of undertakings between the respective legal counsel for Exelar and TSI, provided such undertakings are satisfactory to each party's respective legal counsel.

               11.2                      Closing Deliveries of Exelar . At Closing, Exelar will deliver or cause to be delivered the following, fully executed and in form and substance reasonably satisfactory to TSI and OPCO:

  (a)     
copies of all resolutions and/or consent actions adopted by or on behalf of the boards of directors of Exelar evidencing approval of this Agreement, the transactions contemplated by this Agreement, the Technology Transfer Agreement and the Shareholders Agreement;
     
  (b)     
a certificate of an officer of Exelar, dated as of Closing, certifying that (i) each covenant and obligation of Exelar has been complied with in all material respects; and (ii) each representation, warranty and covenant of Exelar is true and correct in all material respects at the Closing as if made on and as of the Closing;

Page 12 of 24



  (c)     
the Shareholders Agreement, executed by Exelar;
 
  (d)     
the Technology Transfer Agreement executed by the Inventor and Exelar;
 
  (e)     
the opinion of legal counsel to Exelar as to the due authorization, execution, delivery and enforceability of this Agreement and the other Closing Documents;
 
  (f)     
the Employment Agreement executed by Len Reiffel;

               11.3                      Closing Deliveries of TSI . At Closing, TSI will deliver or cause to be delivered to OPCO & Exelar the following, fully executed and in form and substance reasonably satisfactory to OPCO & Exelar:

  (a)     
copies of all resolutions and/or consent actions adopted by or on behalf of the boards of directors of TSI evidencing approval of this Agreement, the transactions contemplated by this Agreement, the Technology Transfer Agreement and the Shareholders Agreement;
 
  (b)     
a certificate of an officer of TSI, dated as of Closing, certifying that (i) each covenant and obligation of TSI has been complied with; and (ii) each representation, warranty and covenant of TSI is true and correct in all material respects at the Closing as if made on and as of the Closing;
 
  (c)     
the Shareholders Agreement, executed by TSI;
 
  (d)     
the opinion of legal counsel to TSI as to the due authorization, execution, delivery and enforceability of this Agreement and the other Closing Documents; and
 
  (e)     
a check payable to OPCO for the Initial Funding.

               11.3                      Closing Deliveries of OPCO . At Closing, OPCO will deliver or cause to be delivered to TSI, Exelar, and the Inventor the following, fully executed and in form and substance reasonably satisfactory to TSI, Exelar, and the Inventor:

  (a)     
copies of all resolutions and/or consent actions adopted by or on behalf of the boards of directors of OPCO evidencing approval of this Agreement, the transactions contemplated by this Agreement, the Technology Transfer Agreement and the Shareholders Agreement;
 
  (b)     
a certificate of an officer of OPCO, dated as of Closing, certifying that (i) each covenant and obligation of OPCO has been complied with in all material respects; and (ii) each representation, warranty and covenant of OPCO is true and correct in all material respects at the Closing as if made on and as of the Closing;
 
  (c)     
the Shareholders Agreement, executed by OPCO;
 
  (d)     
the opinion of legal counsel to OPCO as to the due authorization, execution, delivery and enforceability of this Agreement and the other Closing Documents;
 
  (e)     
the Promissory Note in favour of the Inventor;
 
  (f)     
the Share Certificates for the shares to be issued to Exelar under the Technology Transfer Agreement; and
 
  (g)     
the Share Certificates for the shares to be issued to TSI in respect of the Initial Funding.

Page 13 of 24


ARTICLE 12.
TSI DEFAULT

               12.1                      TSI shall provide written notice to Exelar and OPCO at least 30 days prior to a Post-Closing Funding date, that TSI believes that it is likely to be in default on such payment date and the approximate number of days it expects to be in default. In the event that TSI shall fail to provide any of the Post-Closing Funding in a timely manner as contemplated by paragraph 3.2, Exelar shall have the option to provide a notice of default to TSI.

               12.2                      In the event that TSI shall not cure any default within 20 days of receipt by TSI of a notice of default in accordance with paragraph 12.1 above, unless OPCO and Exelar shall otherwise agree in writing, TSI shall forfeit its rights to provide any further funding and acquire any additional shares of OPCO under this Agreement. In addition, Exelar may elect one or more of the following remedies: (a) Exelar may cause OPCO to reclassify all shares of common stock of OPCO owned by TSI and its transferees into non-voting shares (and TSI will cooperate with Exelar and vote in accordance with Exelar's request to amend OPCO's articles of incorporation to provide for such non-voting shares), (b) in the event of a default under sections 3.1(b)(i) or (ii) hereof, OPCO may issue new shares to Exelar at no cost in an amount to bring Exelar to a percentage ownership of the common shares of OPCO equal to the percentage ownership in OPCO which Exelar would have owned had the price per share set forth in section 3.2 hereof been $3 per share instead of $2, (c) in the event of a default under sections 3.1(b)(iii) or (iv) hereof, OPCO may issue new shares to Exelar at no cost in an amount to bring Exelar to a percentage ownership of the common shares of OPCO equal to the percentage ownership in OPCO which Exelar would have owned had the price per share set forth in section 3.2 hereof been $2.50 per share instead of $2 and (d) all TSI designees to the Board of Directors of OPCO (and all subsidiaries thereof) shall be removed and replaced with designees by Exelar,.

               12.3                      In the event that TSI's rights to provide funding are terminated or Exelar avails itself of any of the remedies as set out in paragraph 12.2 above, the Shareholders Agreement shall, upon Exelar's written notice, terminate (except for section 15 thereunder with respect to TSI) and TSI's rights in respect of OPCO shall be limited to those afforded minority shareholders by law.

ARTICLE 13.
TERMINATION

               13.1                      Termination . This Agreement may be terminated at any time prior to the Closing by:

               (a)                      Mutual written agreement of TSI and Exelar;

               (b)                      Exelar, if there has been a breach by TSI or OPCO of any material representation, warranty, covenant or agreement set forth in this Agreement on the part of TSI or OPCO that is not cured, to the reasonable satisfaction of Exelar, within five business days after notice of such breach is given by Exelar (except that no cure period will be provided for a breach by the Company that by its nature cannot be cured);

               (c)                      TSI, if there has been a breach by Exelar or OPCO of any material representation, warranty, covenant or agreement set forth in this Agreement on the part of Exelar or OPCO that is not cured by Exelar or OPCO, to the reasonable satisfaction of TSI, within five business days after notice of such breach is given by TSI (except that no cure period will be provided for a breach by the Investor that by its nature cannot be cured); or

               (d)                      any of the parties transactions contemplated by this Agreement have not been consummated prior to or on March 31, 2004, unless the parties agree to extend such date and which date may be extended to April 30, 2004 to receive any necessary consents and amendments to the NMTB Agreement.

Page 14 of 24


               13.2                      Effect of Termination . In the event of the termination of this Agreement as provided in Section 13.1, this Agreement will be of no further force or effect, provided, however, that no termination of this Agreement will relieve any party of liability for any breaches of this Agreement that are based on a wrongful refusal or failure to perform any obligations.

ARTICLE 14.
MISCELLANEOUS PROVISIONS

               14.1                      Effectiveness of Representations; Survival . Each party is entitled to rely on the representations, warranties and agreements of each of the other parties and all such representation, warranties and agreement will be effective regardless of any investigation that any party has undertaken or failed to undertake. The representation, warranties and agreements will survive the Closing Date and continue in full force and effect until the two (2) year anniversary of the Closing Date.

               14.2                      Further Assurances . Each of the parties hereto will cooperate with the others and execute and deliver to the other parties hereto such other instruments and documents and take such other actions as may be reasonably requested from time to time by any other party hereto as necessary to carry out, evidence, and confirm the intended purposes of this Agreement.

               14.3                      Amendment . This Agreement may not be amended except by an instrument in writing signed by each of the parties.

               14.4                      Expenses . Each party to this Agreement will bear its respective expenses incurred in connection with the preparation, execution, and performance of this Agreement and the transactions contemplated hereby, including all fees and expenses of agents, representatives, counsel, and accountants.

               14.5                      Entire Agreement . This Agreement, the exhibits, schedules attached hereto and the other Closing Documents contain the entire agreement between the parties with respect to the subject matter hereof and supersede all prior arrangements and understandings, both written and oral, expressed or implied, with respect thereto. Any preceding correspondence or offers are expressly superseded and terminated by this Agreement.

               14.6                      Severability . If one or more provisions of this Agreement or any Closing Document is held to be unenforceable under applicable law, such provision will be excluded from the respective Agreement or Closing Document and the balance of this Agreement or Closing Document, as applicable, will be enforceable in accordance with its terms.

               14.                      7 Notices . All notices and other communications required or permitted under to this Agreement must be in writing and will be deemed given if sent by personal delivery, faxed with electronic confirmation of delivery, internationally-recognized express courier (fare prepaid) e-mail to the parties at the following addresses (or at such other address for a party as will be specified by like notice):

               If to Exelar:

                               EXELAR CORPORATION
                               602 Deming Place
                               Chicago, IL 60614
                               Facsimile: •773-871-0171
                               E-Mail: lreiffel@aol.com

               With a copy (which will not constitute notice) to:

Page 15 of 24


                              Gould & Ratner
                               222 N. LaSalle Street
                              Suite 800
                              Chicago, IL 60601
                              Facsimile: 312-236-3241
                              E-Mail: ftannenbaum@gouldratner.com
                              Attention: Fredric D. Tannenbaum

               If to TSI:

                               TSI MEDICAL CORP.
                              810 Peace Portal Drive, Suite 202
                              Blaine, WA 98230
                              Facsimile: 360-•

               With a copy (which will not constitute notice) to:

                               Stephen F.X. O'Neill
                              O'Neill & Taylor PLLC
                              435 Martin Street, Suite 1010
                              Blaine, WA 98230
                              604-687-5792 / 360-332-3300
                              604-687-6650 / 360-332-2291 (fax)
                              "son@stockslaw.com"

               If to OPCO:

                               Logan B. Anderson
                              810 Peace Portal Drive
                              Suite 203
                              Blaine, WA 98230

               With a copy (which will not constitute notice) to:

                               Cane & Associates
                              3199 E. Warm Springs Road, Suite 200
                              Las Vegas, NV 89120

All such notices and other communications will be deemed to have been received (a) in the case of personal delivery, on the date of such delivery, and (b) in the case of a fax, e-mail or delivery by internationally-recognized express courier, one business day after such notice or communications has been sent

               14.8                      Headings . The headings contained in this Agreement are for convenience purposes only and will not affect in any way the meaning or interpretation of this Agreement.

               14.9                      Benefits . This Agreement is and will only be construed as for the benefit of or enforceable by those persons party to this Agreement.

               14.10                      Assignment . This Agreement may not be assigned (except by operation of law) by any party without the consent of the other parties.

Page 16 of 24


               14.11                      Governing Law . This Agreement will be governed by and construed in accordance with the laws of the State of Nevada applicable to contracts made and to be performed therein. All actions brought to interpret or enforce this Agreement shall be exclusively brought either in the courts located in Seattle, Washington or in Chicago, Illinois and each party waives any defenses regarding lack of personal jurisdiction, lack of venue or forum non conveniens.

               14.12                      Construction . The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rule of strict construction will be applied against any party.

               14.13                      Counterparts . This Agreement may be executed in one or more counterparts, all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need not sign the same counterpart.

               14.14                      Fax or E-Mail Execution . This Agreement may be executed by delivery of executed signature pages by fax or e-mail and such fax or e-mail execution will be effective for all purposes provided that the signatories will promptly provide originals to the other signatories.

               14.15                      Schedules and Exhibits . The schedules and exhibits are attached to this Agreement and incorporated herein.

               14.16                      Independent Legal Advice . Exelar acknowledges that O'Neill & Taylor PLLC have acted solely for TSI in the negotiation and execution of this Agreement and Exelar has received the independent legal advice of its independent legal counsel.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Page 17 of 24


                IN WITNESS WHEREOF the parties hereto have executed this agreement as of the day and year first above written.

EXELAR CORPORATION
a Delaware corporation by its
authorized signatory:
 
   
/s/ Leonard Reiffel  
Signature of Authorized Signatory  
   
   
Name of Authorized Signatory  
   
   
Position of Authorized Signatory  
   
   
   
TSI MEDICAL CORP.
a Nevada corporation by its
authorized signatory:
 
   
/s/ Harold C. Moll  
Signature of Authorized Signatory  
   
   
Name of Authorized Signatory  
   
   
Position of Authorized Signatory  
   
   
   
EXELAR MEDICAL CORPORATION
a Nevada corporation by its
authorized signatory:
 
   
/s/ Logan B. Anderson  
Signature of Authorized Signatory  
   
   
Name of Authorized Signatory  
   
   
Position of Authorized Signatory  

Page 18 of 24


SCHEDULE A
To
Technology Acquisition and Funding Agreement
Among Exelar Corporation and
TSI Medical Corp. and OPCO
Dated March 22, 2004

 

 

DESCRIPTION OF PATENTS


PATENTS AND PATENT APPLICATIONS

1.      US Provisional 60/506,792 "HYDRA"
 
2.      US Provisional 60/472,080 "SOCC"
 
3.      US Patent 5,974,112--"SHIELD"
 
4..      European Patent Appln No 98960301.4 "SHIELD-EPO"

 


SCHEDULE B
To
Technology Acquisition and Funding Agreement
Among Exelar Corporation and
TSI Medical Corp. and OPCO
Dated March 22, 2004

 

 

INTENTIONALLY DELETED


SCHEDULE C
To
Technology Acquisition and Funding Agreement
Among Exelar Corporation and
TSI Medical Corp. and OPCO
Dated March 22, 2004

 

 

TECHNOLOGY TRANSFER AGREEMENT


TECHNOLOGY TRANSFER AGREEMENT

THIS AGREEMENT made effective as of the • day of March, 2004, between:

AMONG:

EXELAR CORPORATION , a Delaware corporation of 602 Deming Place, Chicago, IL 60614

(hereafter called "Exelar")

AND:

LEN REIFFEL , of 602 Deming Place, Chicago, IL 60614

(hereafter called the "Inventor")

AND:

EXELAR MEDICAL CORPORATION , a Nevada corporation having its registered address at 3199 E. Warm Springs Road, Suite 200 Las Vegas, NV 89120

(hereafter called "OPCO")

WHEREAS:

I.     
Exelar is the owner of an invention and related apparatus that has been granted and has applied for United States and foreign patents which invention is held in the name of the Inventor.
 
II.     
The parties have agreed to enter into this agreement to reflect the sale by Exelar and the purchase by OPCO of all property, including all patents, know -how and intellectual property, relating to the invention and the apparatus.

NOW THEREFORE , in consideration of the mutual covenants contained in this Agreement and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

DEFINITIONS

1. In this Agreement:



  (a)     
"Apparatus" means an apparatus for control of photon beam therapeutic radiation doses using superconducting magnets described in the Patents and that incorporates any of the Patents, the Know-how and/or the Intellectual Property;
 
  (b)     
"Improvement" means any modification or variant of the Apparatus and the Invention, whether patentable or not, which, if manufactured, used, or sold, would fall within the scope of the Apparatus, the Invention or at least one claim of at least one of the Patents;
 
  (c)     
"Intellectual Property" means all copyrights, patent rights, trade secret rights, trade names, trademark rights, process information, technical information, contract rights and obligations including those under that certain Subagreement No. 2000-106800-Exelar -Reiffel by and between National Medical Technology Testbed Inc. and Exelar (the "NMTB Agreement"), designs, drawings, inventions and all other intellectual and industrial property rights of any sort related to or associated with Invention and the Apparatus;
 
  (d)     
"Invention" means the inventions described in the Patents and embodied in the Apparatus;
 
  (e)     
"Inventor" means Len Reiffel;
 
  (f)     
"Know-how" means all know-how, knowledge, expertise, inventions, works of authorship, prototypes, technology, information, know-how, materials and tools relating thereto or to the design, development, manufacture, use and commercial application of the Invention and the Apparatus;
 
  (g)     
"Patents" means the Patents and patent applications described in Schedule A and any other patent that may be issued in connection with the Invention or the Apparatus or any Improvement;
 
  (h)     
"Technology" means the Apparatus, the Invention, the Patents, the Know-How and the Intellectual Property.
 
TRANSFER BY EXELAR
 
2.  

  (a)     
Subject to the terms and conditions of this Agreement, and the delivery of the consideration as provided in this Agreement, Exelar hereby sells, assigns and transfers to OPCO all of the Exelar's right, title and interest in and to the Technology including the following assets free and clear of all liens, charges, encumbrances and security interests except for any rights of National Medical Technology Testbed Inc. under the NMTB Agreement and Promissory Note:
 
   
(i)
the Invention;

2



   
(ii)     
the Apparatus;
 
   
(iii)     
the Patents;
 
   
(iv)     
the Know-how;
 
   
(v)     
the Intellectual Property.
 
  (b)     
Exelar and the Inventor agree to assist OPCO in every legal way to evidence, record and perfect the assignment evidenced by this Agreement and to apply for and obtain recordation of and from time to time enforce, maintain, and defend the assigned rights. To the extent that any of the Intellectual Property is a provisional patent, Inventor will cooperate with Exelar and the U.S. Patent and Trademark Office to attempt to obtain a final grant of said provisional patents and, to the extent any such provisional patents are actually issued in Inventor's name, Inventor shall promptly assign and transfer, for no cost (except the filing and recordation fees which will be borne by OPCO), to OPCO. If OPCO is unable for any reason whatsoever to secure Exelar or the Inventor's signatures to any document it is entitled to under this Agreement, Exelar and the Inventor hereby each irrevocably designate and appoint OPCO and its duly authorized officers and agents, as their respective agents and attorneys -in- fact with full power of substitution to act for and on their behalf and instead of each of Exelar and the Inventor, to execute and file any such document or documents and to do all other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by each of Exelar and the Inventor.
 
  (c)     
If, after the date of this Agreement, Exelar or the Inventor develops or discovers, or is a co-developer or co-discoverer of any Improvement, then the Inventor or Exelar shall promptly sell, assign and transfer the Improvement to OPCO without the payment of any additional payment or consideration.
 
  (d)     
OPCO will have full control and discretion over the manufacturing of the Apparatus, including the selection and specification of components and materials.
 
  (e)     
OPCO will have full control and discretion over the marketing and commercial exploitation of the Apparatus, the Invention, Patents, Know-how and Intellectual Property.
 
  (f)     
Exelar and the Inventor shall communicate to OPCO all Know-how and Intellectual Property in the possession of Exelar and the Inventor reasonably relevant to the design, manufacture, marketing, and use of the Apparatus and the Invention. Exelar and the Inventor will continue to communicate to OPCO all such further Know-how and Intellectual Property as comes into Exelar or the Inventor's possession.
 
  (g)     
All Know-how and technical information in the possession of Exelar and the Inventor reasonably relevant to the design, manufacture, marketing, and use of the Apparatus shall be deemed to be confidential information. Exelar and the

3



   
Inventor shall not disclose or authorize the disclosure of such information to any third party, except as expressly permitted by OPCO in writing. Exelar and the Inventor shall take reasonable precautions to prevent the unauthorised disclosure to third parties of all such confidential information.
 
  (h)     
The obligations of Exelar and Inventor hereunder are subject to and conditioned on compliance in full, after all applicable cure periods, by OPCO under the Promissory Note (as defined under the Funding Agreement). In the event of a default under the Promissory Note, after all applicable cure periods, Inventor may terminate and cancel its obligations under this Agreement and receive an immediate reconveyance by OPCO of its respective conveyances, free and clear of all liens, claims, security interests and encumbrances of the Patents (together with any Improvements thereon and Intellectual Property related thereto) as indicated on Schedule A., of the Patents of Inventor. If in such case Inventor is unable for any reason whatsoever to secure OPCO's signatures to any document it is entitled to under this section, OPCO hereby irrevocably designate and appoint Inventor and its duly authorized officers and agents, as their respective agents and attorneys -in-fact with full power of substitution to act for and on their behalf and instead of OPCO, to execute and file any such document or documents and to do all other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by OPCO.

CONSIDERATION

3.  
     
 
(a)     
The consideration of the sale, assignment and transfer of the Invention, Apparatus, Patents, Know-how and Intellectual Property, shall be as follows:
 
   
(i)     
the assumption by OPCO of Exelar's obligation to pay the Inventor $500,000 in respect of the acquisition of the Technology from the Inventor (the "Exelar Obligation");
 
   
(ii)     
the issuance by OPCO to Exelar of a total of 2,280,000 shares of its common stock (the "Shares") on execution of this Agreement.
 
 
(b)     
All shares of OPCO's common stock issued by OPCO pursuant to this Agreement (the "Shares") will be governed by the following:
 
   
(i)     
All Shares will be issued as "restricted shares", as contemplated by the Securities Act of 1933 (the "1933 Act"). Exelar acknowledges and agree that the Shares have not been registered under the 1933 Act or applicable state "Blue Sky" laws and, therefore, the Shares may not be resold, transferred or hypothecated without the registration of the Shares, or an opinion of counsel satisfactory to OPCO to the effect that such registration is not necessary;

4



    (ii) 
All certificates representing the Shares will be endorsed with the following legend:
       
     
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT"), AND HAVE BEEN OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, TRANSFERRED, PLEDGED OR RESOLD OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER THE APPLICABLE PROVISIONS OF THE ACT OR ARE EXEMPT FROM SUCH REGISTRATION REQUIREMENTS." ;
 
    (iii)     
All Shares will be issued to Exelar based on the representations and warranties of Exelar that:
 
     
(A)     
Exelar has not offered or sold the Shares within the meaning of the 1933 Act;
 
     
(B)     
Exelar is acquiring the Shares for its own account for investment, with no present intention of dividing any interest with others or of reselling or otherwise disposing of all or any portion of the same;
 
     
(C)     
Exelar does not intend any sale of the Shares either currently or after the passage of a fixed or determinable period of time or upon the occurrence or non -occurrence of any predetermined event or circumstance;
 
     
(D)     
Exelar has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for or which is likely to compel a disposition of the Shares;
 
     
(E)     
Exelar is not aware of any circumstances presently in existence which are likely in the future to prompt a disposition of the Shares;
 
     
(F)     
The Shares were offered to Exelar in direct communication between Exelar and OPCO and not through any advertisement of any kind;
 
     
(G)     
Exelar has the financial means to bear the economic risk of an investment in the Shares.

5


ACCEPTANCE OF ASSUMPTION BY INVENTOR

4.     
The Inventor hereby consents and accepts the assumption of the Exelar Obligation by OPCO and agrees to extinguish the liability of Exelar to him in consideration of the issuance at closing of promissory notes of OPCO in favour of the Inventor as follows:
 
   
(i)     
a promissory note in the principal amount of $200,000 payable with no interest on the date which is 90 days following closing and a payment in the principal amount of $300,000 payable with no interest on the date which is 180 days following closing.

PATENTS

5.     
The Inventor agrees to execute assignments of the Patents, including any patent applications, in forms registerable with the applicable Patent authorities, at closing and without the payment of any further amount to Inventor. OPCO will undertake all steps and incur all expenses to maintain the Patents in good standing with the United States Patent Office. OPCO will pursue the granting of any patents pending and foreign patents with respect to the Patents in Canada, the European Economic Community, Australia and Japan and such other jurisdictions as the parties may agree with respect to the HYDRA and SOCC Patents. The Inventor will assist OPCO in pursuing the granting of foreign patents.

WARRANTIES AND REPRESENTATIONS

6.    
     
  (a)     
The Inventor and Exelar jointly and severally warrant and represent to OPCO that:
 
   
(i)     
Exelar is the sole owner of the Invention, the Apparatus, the Patents, the Know-how and the Intellectual Property free and clear of all liens, charges, encumbrances and security interests except for the NMTB Agreement;
 
   
(ii)     
the Inventor holds the Patents in his name as trustee for Exelar;
 
   
(iii)     
Exelar has the power to sell, assign and transfer all of its right, title and interest in and to the Invention, the Apparatus, the Patents, the Know-how and the Intellectual Property to OPCO except for rights under the NMTB Agreement;
 
   
(iv)     
Exelar and the Inventor have not made, granted or entered into any assignment, encumbrance, license or other agreement affecting the

6



     
Invention, the Apparatus, the Patents, the Know- how and the Intellectual Property except pursuant to the NMTB Agreement;
       
    (v) 
Exelar and the Inventor are not aware of any violation, infringement or misappropriation of any third party's rights (or any claim thereof) by the ownership, development, manufacture, sale or use of the Invention, the Apparatus, the Patents, the Know-how and the Intellectual Property;
       
    (vi) 
the use of the Apparatus by Exelar and the Inventor has never given rise to any complaint alleging infringement of any patent, trademarks or other intellectual property rights of any other person;
       
    (vii) 
Exelar and the Inventor were not acting within the scope of employment of any third party when conceiving, creating or otherwise performing any activity with respect to the Invention, the Apparatus, the Patents, the Know-how and the Intellectual Property;
       
    (viii) 
Exelar and the Inventor are not aware of any questions or challenges with respect to the patentability or validity of any claims of any existing patents or patent pendings relating to the Invention, the Apparatus, the Patents, the Know-how and the Intellectual Property;
       
    (ix)  The Patents, including any patent applications, have been filed with the appropriate Patent authorities in accordance with all required laws and regulations and are in good standing.

JOINT AND SEVERAL OBLIGATIONS

7.      All obligations, agreements and representations and warranties of the Inventor and Exelar in this Agreement are joint and several.

ENTIRE AGREEMENT

8.     
This Agreement constitutes the entire agreement between the parties, relating to the subject matter hereof and supersedes every previous agreement, communication, expectation, negotiation, representation or understanding, whether oral or written, express or implied, statutory or otherwise.

GOVERNING LAW

9.     
This Agreement shall be construed in accordance with, and governed by, the laws of the State of Nevada. All actions brought to interpret or enforce this Agreement shall be exclusively brought either in the courts located in Seattle, Washington or in Chicago, Illinois and each party waives any defenses regarding lack of personal jurisdiction, lack of venue or forum non conveniens.

7


HEADINGS

10.     
The headings are inserted solely for convenience of reference and shall not be deemed to restrict or modify the meaning of the Articles to which they pertain.

MODIFICATION AND WAIVER

11.     
No cancellation, modification, amendment, deletion, addition or other change in this Agreement or any provision hereof, or waiver of any right or remedy hereby provided, shall be effective for any purpose unless specifically set forth in writing, signed by the party to be bound thereby. No waiver of any right or remedy in respect of any occurrence or event on one occasion shall be deemed a waiver of such right or remedy in respect of such occurrence or event on any other occasion.

FURTHER ASSURANCE

12.     
The Parties shall execute such further documents and do such further things as may be necessary to give full effect to the provisions of this Agreement and the intent embodied herein.

GENDER

13.     
Words importing the masculine gender include the feminine or neuter, words in the singular include the plural, words importing a corporate entity include individuals and vice versa.

EQUAL PARTICIPATION IN DRAFTING

14.     
The parties have equally participated in the drafting of the within Agreement, each having had the opportunity to be independently represented by counsel. The Inventor and Exelar acknowledge that O'Neill & Taylor PLLC have acted solely for OPCO in connection with the preparation, negotiation and execution of this Agreement and the Inventor and Exelar have been advised to obtain the advice of their independent legal counsel in entering into this Agreement.

CLOSING

15.     
Closing shall take place at the offices of OPCO forthwith on execution of this Agreement. At the closing, OPCO shall deliver the Shares to Exelar, OPCO shall deliver the promissory notes referred to in Paragraph 4 of this Agreement to the Inventor and the Inventor and Exelar shall deliver the assignments of Patents referred to in Paragraph 5 of this Agreement.

8


TIME OF THE ESSENCE

16.
Time shall be of the essence of this Agreement and all provisions hereof.

IN WITNESS WHEREOF, the parties hereto have caused these presents to be executed under their corporate seals and the hands of their proper officers duly authorized in that behalf.

SIGNED, SEALED AND DELIVERED      
BY LEN REIFFEL      
in the presence of:     
     
     
     
Signature     
     
    LEN REIFFEL  
Name     
     
     
Address     
     
     
     

EXELAR CORPORATION
By its authorized signatory:
 
   
   
   
Name
Title
 
   
   
EXELAR MEDICAL CORPORATION
By its authorized signatory:
 
   
   
   
Name
Title
 

9


SCHEDULE A

PATENTS AND PATENT APPLICATIONS

1.      US Provisional 60/506,792 "HYDRA"
 
2.      US Provisional 60/472,080 "SOCC"
 
3.      US Patent 5,974,112--"SHIELD"
 
4..      European Patent Appln No 98960301.4 "SHIELD-EPO"

Items 1 and 2 above are two provisional patents and are part of the Patents under this Agreement. In the event of an event of default under the Promissory Note, after all cure periods, OPCO will promptly re-convey free and clear ownership to items 3 and 4 to Inventor.

10


SCHEDULE D
To
Technology Acquisition and Funding Agreement
Among Exelar Corporation and
TSI Medical Corp. and OPCO
Dated March 22, 2004

 

 

SHAREHOLDERS AGREEMENT


SHAREHOLDERS AGREEMENT

THIS AGREEMENT dated for reference the • day of March, 2004.

AMONG:

TSI MEDICAL CORP.
a Nevada corporation
("TSI")

OF THE FIRST PART

AND:

EXELAR CORPORATION ,
a Delaware corporation
("Exelar")

OF THE SECOND PART

AND:

EXELAR MEDICAL CORPORATION
a Nevada corporation
(the "Corporation")

OF THE THIRD PART

WHEREAS:

A.                    TSI and Exelar (collectively the "Shareholders") are all of the shareholders of the Corporation, a Nevada close corporation, governed by Nevada Revised Statutes 78A.

B.                    The Shareholders are entering into this Agreement to regulate the exercise of the corporate power and the management of the business and affairs of the Corporation and the relationship between the parties as shareholders.

C.                    The Shareholders intend that this Agreement shall be a shareholders agreement within the meaning of Section 78A.070 of the Nevada Revised Statutes and be binding on the Corporation and its directors.

NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the foregoing and of the mutual covenants and agreements hereinafter contained, and of $1.00 now paid by each of the parties hereto to the other, the receipt and sufficiency of which is hereby

1


acknowledged, and for other good and valuable consideration, the parties hereto have agreed and do hereby agree as follows:

1..                     Definitions. The following terms will have the following meanings for all purposes of this Agreement.

  (a)     
"Agreement" shall mean this Agreement, and all schedules and amendments to in the Agreement.
 
  (b)     
"Budget" means the budget that is attached as Schedule E to the Technology Acquisition and Funding Agreement;
 
  (c)     
"Common Stock" means the common stock of the Corporation, par value $0.001 per share.
 
  (d)     
"Corporation" shall mean Exelar Medical Corporation, a Nevada corporation.
 
  (e)     
"Technology Acquisition and Funding Agreement" means the agreement among the parties with respect to the acquisition of Technology by and funding of the Corporation being executed concurrent with this Agreement.

2.                     Agreement to Vote . Each of the Shareholders, as holders of Common Stock, hereby agrees on behalf of itself and any transferee or assignee of any such shares of the Common Stock, to hold all of the shares of Common Stock registered in its name (and any securities of the Corporation issued with respect to, upon conversion of, or in exchange or substitution of the Common Stock, and any other voting securities of the Corporation subsequently acquired by such Party) (hereinafter collectively referred to as the "Covered Shares") subject to, and to vote the Covered Shares at a regular or special meeting of Shareholders (or by written consent) in accordance with, the provisions of this Agreement.

3.                     Board Size . The holders of Covered Shares shall vote at a regular or special meeting of Shareholders (or by written consent) such shares that they own (or as to which they have voting power) to ensure that the size of the Board shall be set and remain at five (5) directors;

4.                     Election of Directors . In any election of directors of the Corporation, the Shareholders shall each vote at any regular or special meeting of Shareholders (or by written consent) such number of shares of Common Stock then owned by them (or as to which they then have voting power) as may be necessary to elect two (2) directors nominated by TSI and three (3) directors nominated by Exelar. Any subsidiaries of the Corporation shall also have Boards of Directors comprised the same way, except that they shall be selected by the Board of the Corporation.

5.                     Removal . Any director of the Corporation may be removed from the Board in the manner allowed by law and the Corporation's Certificate of Incorporation and Bylaws, but with respect to a director designated pursuant to Section 4 above, only upon the vote or written consent of the Shareholder entitled to designate such director. Upon any such removal, the Shareholders shall vote on behalf of a successor director based on the nomination of the party whose director was removed.

2


6.                     Quorum . During the term of this agreement, the quorum for a meeting of the Board of Directors shall be four directors and no business shall be conducted unless four directors are present.

7.                     Prohibitions . The parties agree that during the term of this Agreement, the Corporation will not without the prior written consent of TSI and Exelar:

    (i)     
alter or change the Corporation's Articles of Incorporation or Bylaws;
 
    (ii)     
authorize or designate any equity security (or security convertible into an equity security such as a warrant, option or convertible instrument) other than the Common Stock;
 
    (iii)     
increase the number of shares of capital stock reserved for issuance under, or authorize the creation of any employee, officer, director or consultant stock purchase or stock option plan;
 
    (iv)     
change the size of the Board of Directors;
 
    (v)     
increase or decrease the total number of authorized shares of Common Stock or any other class of stock;
 
    (vi)     
incur borrowings or other indebtedness individually or in the aggregate in excess of $50,000, excluding trade payables incurred in the ordinary course of business;
       
    (vii) 
pay or declare any dividend or distribution on, or redeem, repurchase, or otherwise acquire, any shares of capital stock (or make any payment or set aside a sinking fund for such purpose);
       
    (viii) 
make loans or advances except in the ordinary course of business; 
       
    (ix) 
approve any merger or consolidation of the Corporation or any sale of all or substantially all of the assets of the Corporation or approve or facilitate any other event resulting in a change in control of the Corporation;
       
    (x) 
mortgage or pledge, or create a security interest in, or otherwise dispose of any material asset; 
       
    (xi) 
form or constitute any audit, compensation, executive or other committee of the Board;
       
    (xii) 
authorize any action that results in any voluntary bankruptcy, assignment for the benefit of creditors, acceleration of third party obligations, assignment for the benefit of creditors, confession of judgment, dissolution or liquidation of the Corporation or any reclassification of the Corporation's capital stock;

3


    (xiii) 
hire or fire the CEO, COO, CFO or any other officer having similar  responsibilities;
       
    (xiv) 
enter into any transaction with an affiliate;
       
    (xv) 
incur capital expenditures in excess of $250,000 in any calendar year; or
       
    (xvi) 
pay total compensation to any officer, director or employee of the  Corporation (other than as provided in the Budget) including the granting  of any option, warrant or other convertible security.

8.                    Legend on Share Certificates . Each certificate representing any Covered Shares shall be endorsed by the Corporation with a legend reading substantially as follows:

"The shares evidenced hereby are subject to a Shareholder Agreement (a copy of which may be obtained upon written request from the issuer), and by accepting any interest in such shares the person accepting such interest shall be deemed to agree to and shall become bound by all the provisions of said Shareholder Agreement."

9.                    No Liability for Election of Recommended Directors . Neither the Corporation, the parties, nor any officer, director, Shareholder, partner, employee or agent of such Party, makes any representation or warranty as to the fitness or competence of the nominee of any Party hereunder to serve on the Corporation's Board by virtue of such Party's execution of this Agreement or by the act of such Party in voting for such nominee pursuant to this Agreement. The Corporation's by-laws and certificate of incorporation shall have the broadest indemnification provisions possible for directors and the Board shall purchase, to the extent feasible and cost effective, directors and officers liability insurance policies.

10.                   Grant of Proxy . Should the provisions of this Agreement be construed to constitute the granting of proxies, such proxies shall be deemed coupled with an interest and are irrevocable for the term of this Agreement.

11.                   Specific Enforcement . It is agreed and understood that monetary damages would not adequately compensate an injured Party for the breach of this Agreement by any Party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order. Further, each Party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach.

4


12.                   Execution by the Corporation . The Corporation, by its execution in the space provided below, agrees that it will cause the certificates evidencing the Covered Shares to bear the legend required by Section 8 herein, and it shall supply, free of charge, a copy of this Agreement to any holder of a certificate evidencing shares of capital stock of the Corporation upon written request from such holder to the Corporation at its principal office. The parties hereto do hereby agree that the failure to cause the certificates evidencing the Covered Shares to bear the legend required by Section 8 herein and/or failure of the Corporation to supply, free of charge, a copy of this Agreement as provided under this Section 12 shall not affect the validity or enforcement of this Agreement.

13.                   Captions . The captions, headings and arrangements used in this Agreement are for convenience only and do not in any way limit or amplify the terms and provisions hereof.

14.                   Notices . Any notice required or permitted by this Agreement shall be in writing and shall be sent prepaid registered or certified mail, return receipt requested, addressed to the other Parties at the addresses shown below or at such other addresses for which such Party gives notice hereunder. Such notice shall be deemed to have been given three (3) days after deposit in the mail.

15.     
Term . This Agreement shall terminate and be of no further force or effect upon (a) the termination of TSI's funding obligations or exercise of other remedies by Exelar under paragraph 12.3 of the Technology Acquisition and Funding Agreement, (b) the acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Corporation or a sale of all or substantially all of the assets of the Corporation, (c) February 15, 2010 or (d) the written consent of all the parties.
 
 
Notwithstanding any termination of this Agreement, if at any time after the termination of this Agreement either of TSI or Exelar (or their transferees, successors or assigns) (a "Seller") desires to sell all or any part of the Covered Shares owned by such Seller to any person or entity other than the Corporation or the other shareholder (the "Buyer"), TSI (if it is not the Seller) or Exelar if it is not the Seller) (the "Tagger") shall have the right to sell to the Buyer, as a condition to such sale by the Seller at the same price per share and on the same terms and conditions as the proposed sale by the Seller, the number of Covered Shares equal to the product of (i) the aggregate number of Covered Shares proposed to be sold by the Seller multiplied by (ii) a fraction with a numerator equal to the number of Covered Shares that Seller owns and a denominator equal to the total number of Covered Shares owned by such Seller and each Tagger who wishes to exercise tag-along rights in accordance with this section. Prior to any such proposed sale, such Seller shall deliver to the Tagger and to the Corporation a notice of proposed sale (the "Notice"), which discloses the identity of the Buyer, the Covered Shares proposed to be sold, the total number of Covered Shares owned by the Seller, the terms and conditions, including price, of the proposed sale, and any other material facts relating to the proposed sale. If the Tagger wishes to so participate in any sale under this section 15, it shall notify the Seller in writing of such intention as soon as practicable after such holder's receipt of the Notice, and in any event within twenty days after the date the Notice was received. Prior to the sale of any Covered Shares to be sold by Seller and/or Tagger hereunder, such person shall deliver to the Corporation (in a form reasonably acceptable to the Corporation) a written

5



 

agreement of the proposed Buyer agreeing to become a party to this Agreement as a Shareholder.

Notwithstanding any termination of this Agreement, (a) in the event that Shareholders owning a majority of the Covered Shares on a fully-diluted as if converted basis (the "Majority") desires to sell all or in excess of 50% of their Covered Shares pursuant to a binding agreement with a non-affiliate in an arm's length transaction for an all cash non-contingent price (the "Offer"), the Majority shall send to the other Shareholders (the "Others") a written notice of the price, terms and conditions of the Offer, a copy of the Offer, the name, address and business of the proposed purchaser ("Buyer"), and such other information concerning the Buyer as the Others may reasonably require.

In the event that the Offer requires that the Others sell the same percentage of its Shares to be sold by the Majority pursuant to the Offer (the "Drag-Along Shares"), or the Majority believes in its reasonable opinion that the Offer would be enhanced if the Others sold the Drag-Along Shares (the "Drag-Along"), then the Majority shall provide written notice to the Others of the Drag-Along. The Others (including their transferees) shall be obligated to sell the Drag-Along Shares on the same economic terms and conditions as the Majority sells its Shares pursuant to the Offer.

If at any time a bona fide offer from an unaffiliated third party is made to the Corporation to purchase the Corporation, whether by merger, consolidation, sale of all or substantially all of the assets of the Corporation or a sale of all or substantially all of the capital stock of the Corporation, in one transaction or a series of transactions for a purchase price at least 90% in cash (an "Approved Sale") and the Approved Sale is approved by the Majority, each Shareholder will consent to and raise no objections to the Approved Sale, and (a) if the Approved Sale is structured as a sale of stock, each Shareholder will agree to sell, and will sell, all of such holder's equity securities in the Corporation on the terms and conditions (including any escrow or indemnification provisions) approved by the holders of a majority of the voting power of the Corporation, (b) if the Approved Sale is structured as a merger or consolidation, each Shareholder will vote in favor thereof and will not exercise any dissenters' rights of appraisal such Shareholder may have under law, including Delaware Corporation law and (c) if the Approved Sale is structured as a sale of all or substantially all of the assets of the Corporation and a subsequent dissolution and liquidation of the Corporation, each Shareholder will vote in favor thereof and will vote in favor of the subsequent dissolution and liquidation of the Corporation. Each Shareholder will take all necessary actions in connection with consummation of the Approved Sale as are reasonably requested by the holders of a majority of the voting power of the Corporation. The Corporation and each Shareholder hereby agree to cooperate fully in any Approved Sale and not to take any action prejudicial to or inconsistent with such Approved Sale. Without limiting the generality of the foregoing, each Shareholder will, upon request, deliver an executed instrument of transfer with respect to their equity securities in the Corporation in escrow (pending receipt of the purchase price therefor) to counsel for the Corporation.

6


16.                   Manner of Voting . The voting of shares pursuant to this Agreement may be effected in person, by proxy, by written consent, or in any other manner permitted by applicable law.

17.                   Amendments and Waivers . Any term hereof may be amended and the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Party or Parties benefited by such term. Any amendment or waiver so effected shall be binding upon the Parties hereto.

18.                   Stock Splits, Stock Dividends, etc . In the event of any issuance of shares of the Corporation's voting securities hereafter to any of the Parties hereto (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such shares shall become subject to this Agreement and shall be endorsed with the legend set forth in Section 8.

19.                   Severability . Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

20.                   Resale or Transfer . During the currency of this Agreement, Exelar and TSI shall not transfer and the Company shall not approve a transfer of any of the Covered Shares without the written approval of the other.

21.                   Binding Effect . In addition to any restriction or transfer that may be imposed by any other agreement by which any Party hereto may be bound, this Agreement shall be binding upon the Parties, their respective heirs, successors, assigns and transferees of any of the Covered Securities affected hereby and to such additional individuals or entities that may become Shareholders of the Corporation and that desire to become Parties hereto; provided that for any such transfer to be deemed effective, the transferee shall have executed and delivered an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any transferee reasonably acceptable to the Corporation, such transferee shall be deemed to be a Party hereto as if such transferee's signature appeared on the signature pages hereto. By their execution hereof or any Adoption Agreement, each of the Parties hereto appoints the Corporation as its attorney-in-fact for the purpose of executing any Adoption Agreement which may be required to be delivered hereunder.

21.                   Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without regard to conflicts of law principles thereof. All actions brought to interpret or enforce this Agreement shall be exclusively brought either in the courts located in Seattle, Washington or in Chicago, Illinois and each party waives any defenses regarding lack of personal jurisdiction, lack of venue or forum non conveniens.

22.                   Entire Agreement . This Agreement is intended to be the sole agreement of the Parties as it relates to this subject matter and does hereby supersede all other agreements of the Parties relating to the subject matter hereof.

7


23.                   Counterparts . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF the parties hereto have executed this Agreement as of the day and year first above written.

EXELAR CORPORATION
a Delaware corporation by its
authorized signatory:
 
   
   
Signature of Authorized Signatory  
   
   
Name of Authorized Signatory  
   
   
Position of Authorized Signatory  
   
   
TSI MEDICAL CORP.
a Nevada corporation by its
authorized signatory:
 
   
   
Signature of Authorized Signatory  
   
   
Name of Authorized Signatory  
   
   
Position of Authorized Signatory  
   
   
EXELAR MEDICAL CORPORATION
a Nevada corporation by its
authorized signatory:
 
   
   
Signature of Authorized Signatory  
   
   
Name of Authorized Signatory  
   
   
Position of Authorized Signatory  

8


SCHEDULE A
ADOPTION AGREEMENT

This Adoption Agreement ("Adoption Agreement") is executed by the undersigned (the "Transferee") pursuant to the terms of that certain Shareholders Agreement dated as of ________, _______ (the "Agreement") by and among the Corporation and certain of its Shareholders. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Transferee agrees as follows:

(a)         Acknowledgment. Transferee acknowledges that Transferee is acquiring certain shares of the capital stock of the Corporation (the "Stock"), subject to the terms and conditions of the Agreement.

(b)         Agreement. Transferee (i) agrees that the Stock acquired by Transferee shall be bound by and subject to the terms of the Agreement, and (ii) hereby adopts the Agreement with the same force and effect as if Transferee were originally a Party thereto.

(c)         Notice. Any notice required or permitted by the Agreement shall be given to Transferee at the address listed beside Transferee's signature below.

SIGNED, SEALED AND DELIVERED
by the Transferee in the presence of:
   
     
     
Signature of Witness   Signature of Transferee
     
     
     
Name of Witness    
     
     
     
Address of Witness    

 


SCHEDULE E
To
Technology Acquisition and Funding Agreement
Among Exelar Corporation and
TSI Medical Corp. and OPCO
Dated March 22, 2004

 

 

BUDGET


EXELAR MEDICAL

BUDGET

  Sources & Uses               Funding                
                     
Sources                              
- proceeds from funding by TSI  $ 325,000    575,000    1,550,000    1,000,000    1,300,000   
                                 
  Total Sources   $ 325,000    575,000    1,550,000    1,000,000    1,300,000   
                                 
  Uses                            
 NMTB Contract Buyout  $ 50,000    50,000    50,000       
 Purchase of IP      200,000    300,000       
Corporate Uses                              
 Selling, General &  $ 113,000    119,000    255,000    153,000    200,000   
   Administrative                             
 Clinical Studies & Research  $ 156,000    200,000    262,000    259,000    335,000   
 Capital Expenditures  $ 6,000    6,000    36,000    36,000    47,000   
 Reserve  $     647,000    552,000    718,000   
                                 
  Total Uses   $ 325,000    575,000    1,550,000    1,000,000    1,300,000   


SCHEDULE F
To
Technology Acquisition and Funding Agreement
Among Exelar Corporation and
TSI Medical Corp. and OPCO
Dated March 22, 2004

 

 

EMPLOYMENT AGREEMENT


EMPLOYMENT AGREEMENT

THIS AGREEMENT made as of the 15th day of March, 2004

BETWEEN:

Exelar Medical Corporation of NV

(the "Corporation")

OF THE FIRST PART

AND:

LEN REIFFEL, of 602 Deming Place, Chicago, II 60614

(the "Employee")

OF THE SECOND PART

WHEREAS:

A.                    The Corporation wishes to engage the services of the Employee to act as Chairman and Chief Technical Officer of the Corporation.

B.                    The Employee has agreed to accept such engagement upon the terms and conditions as hereinafter set forth.

NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the premises and the mutual covenants herein contained the parties agree as follows:

1.                    The Corporation hereby appoints the Employee to the position of Chairman of the Board and Chief Technical officer of the Corporation and retains him to supervise and deal with the following responsibilities:

(a) Perform the usual duties of Chairman of the Board

(b) Assemble the Corporation's staff

(c) Manage the Corporation's technical activities

(d) In concert with other key officers and interested parties, devise and implement product development and commercialization strategies for the company's technology

(e) Represent the company, as appropriate, in scientific, public-relations, financial and other contexts.

(f) Protect and enhance, where possible, the Intellectual Property of the Corporation.


2.                    This Agreement shall be for an initial term of three (3) years commencing on the date of this Agreement and shall be automatically renewed at the end of each term for an additional one (1) year unless notice to the contrary is given by either the Corporation or the Employee to the other at least six months prior to the expiration of any term.

3.                    The remuneration payable to the Employee shall be $175,000 per year payable monthly in two equal payments on the 15th day and last business day of each month commencing on the date of this Agreement.

4.                    In addition to the compensation provided for in paragraph 3, the Employee shall be entitled to such stock options as may be approved by the Board of Directors of the Corporation and shall be entitled to participate in any employee share purchase or benefit plans as may from time to time be established by the Board of Directors of the Corporation.

5.                    The Employee shall not, during the term of his employment or at any time thereafter, disclose to any person, firm or corporation any information concerning the business or affairs of the Corporation which the Employee may have acquired in the course of or incidental to his employment or otherwise for his own benefit or to the detriment or intended or probable detriment of the Corporation.

6.                    The Employee shall at all times abide by all directions given by the Board of Directors of the Corporation.

7.                    Any notice required to be given under this Agreement shall be in writing and delivered or sent from a post office by prepaid ordinary post addressed to the Employee and to the Corporation at the addresses set out as aforesaid. Any notice shall be deemed given when personally delivered or on the second business day following the day of mailing when mailed.

8.                    This Agreement is a personal service contract and may not be assigned or transferred by the Employee. It is understood that employee has certain other business interests. Employee is permitted to reasonably engage in such other activities so long as such activities do not involve a conflict of interest or interfere with employee's satisfactory discharge of his duties and responsibilities as defined in Section 1

9.                    Notwithstanding Section 2, the Corporation may, terminate the employee for Cause (as defined herein) and the Employee may terminate this Agreement for Good Reason (as defined herein).

10.                   The term "Cause" shall mean: (i) any willful violation by Employee of any material provision of this Agreement causing demonstrable and serious injury to the Corporation; (ii) embezzlement by Employee of funds or property of the Corporation; (iii) fraud or willful misconduct on the part of Employee in the performance of his duties as an employee of the Corporation, or gross negligence on the part of Employee in the performance of his duties as an employee of the Corporation causing demonstrable and serious injury to the Corporation,; or (iv) a felony conviction of Employee based on the actual conduct of the Employee, provided that Cause shall not be deemed to have occurred under sections (i) and (iii) hereof unless the Corporation has given written notice which notice describes in detail the breach asserted and stating that it constitutes notice pursuant to this section, and which breach, if capable of being cured, has not been cured within 60 days after such notice or such longer period of time if Employee proceeds with due diligence not later than ten days after such notice to cure such breach.


11.                   The term "Good Reason" shall mean (i) any breach by the Corporation of any material provision of this Agreement, including, without limitation, the assignment to the Employee of duties inconsistent with his position specified in this Agreement; (ii) relocation of Employee's offices in excess of 20 miles from its current headquarters office location; or (iii) a substantial and continued reduction in the level of support, services, staff, secretarial, office space and accoutrements to a level below which is reasonably necessary or the performance of Employee's duties hereunder, consistent with that of other key Employee employees .

12.                   Upon a termination for Cause, the Corporation shall pay Employee his Base and benefits including vacation pay through the date of termination of employment; and Employee shall receive no severance hereunder. Upon a termination for Good Reason, the Corporation shall immediately pay Employee his remaining base salary for the balance of the term and continue the other benefits in place for the balance of the term.

13.                    The Corporation shall indemnify and hold harmless Employee to the full extent authorized or permitted by law with respect to any claim, liability, action or proceeding instituted or threatened against or incurred by Employee or his legal representatives and arising in connection with Employee's conduct or position at any time as a director, officer, employee or agent of the Corporation or any subsidiary thereof. The Corporation shall not change, modify, alter or in any way limit the existing indemnification and reimbursement provisions relating to and for the benefit of its directors and officers without the prior written consent of the Employee, including any modification or limitation of any directors and officers liability insurance policy.

[REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]


14.                    This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada irrespective of conflict of laws principles. All actions brought to interpret or enforce this Agreement shall be brought in courts located in federal or state Cook County, Illinois.

IN WITNESS WHEREOF the parties have set their hands and seals as of the day and year first above written.

Exelar Medical Corporation
By its authorized signatory:
 
   
   
   
   
Name
Title
 


SIGNED, SEALED AND DELIVERED
BY LEN REIFFEL
in the presence of:
   
     
     
     
Signature of Witness   LEN REIFFEL
     
     
     
Name of Witness    
     
     
     
Address of Witness    



RELAY MINES LIMITED
Suite 3400 Park Place, 666 Burrard Street
Vancouver, BC V6C 3P6

News Release
Current Trading Symbol: RLYM
New Trading Symbol: XLRC

Relay Mines Limited ("Relay") issued the following news release today.

Effective September 13, 2004, Relay's wholly owned subsidiary, TSI Med Acquisition Corp. ("Acquisition Sub") merged with TSI Medical Corp. ("TSI"). TSI has rights to acquire up to 60% of Exelar Medical Corporation ("Exelar Medical"), a company that is developing a patented technology that utilizes small superconducting magnets to focus and control doses of therapeutic radiations for the treatment of cancerous tumors. Under the terms of the merger, a total of 9,492,667 common shares of Relay are being issued to the existing shareholders of TSI in addition 60,000,000 shares currently held by Relay's principal shareholders are being cancelled with the result that upon completion of the issuance of shares to the TSI shareholders, Relay will have 22,859,875 common shares issued and outstanding. Relay will also issue options and warrants to the existing TSI option and warrant holders. In addition, Relay will assume obligations of TSI to issue 500,000 units, with each unit consisting of one common share and one warrant, to subscribers under a recent private placement of TSI and the obligation to issue 300,000 common shares in connection with TSI's acquisition of its interest in Exelar Medical.

Concurrent with the closing of the merger, Mr. Carlo Civelli and Mr. Bruno Mosimann have resigned as directors and officers of Relay, and the following have been appointed:

  Logan Anderson  President, Principal Executive Officer, 
    Treasurer, Principal Financial Officer and 
    a Director 
     
  Derek van Laare  Secretary 
     
  Harold Moll  Director 
     
  Peter Hogendoorn  Director 


Effective September 15, 2004, Relay will complete a second merger with Acquisition Sub and change its name to XLR Medical Corp. No additional shares will be issued in connection with this second merger. Its trading symbol on the NASD OTC Bulletin Board will also change to XLRC to reflect the change of name.

For more information please contact:

Chet Kurzawski, Vice-President Investor Relations
Telephone: 604-676-5247

This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential", "continue" or "proposed" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) our limited operating history; (2) our ability to retain the professional advisors necessary to guide us through our corporate restructuring including, but not limited to, the contemplated merger between TSI Medical Corp. and Relay Mines Limited; (3) the risks inherent in the investigation, involvement and acquisition of a new business opportunity; (4) unforeseen costs and expenses; (5) potential litigation with our shareholders and/or former or current investors; (6) the companies' abilities to comply with federal, state and local government regulations; and (7) other factors over which we have little or no control.